

CURRICULUM VITAE

Paul P. Dobesh, Pharm.D., FACC, FAHA, FCCP, BCPS, BCCP

PERSONAL INFORMATION

Address	College:	University of Nebraska Medical Center College of Pharmacy Department of Pharmacy Practice and Science 986145 Nebraska Medical Center Omaha, Nebraska 68198-6145 Office: (402) 559-3982 Fax: (402) 559-5673 Cell: (402) 214-5498 Email: pdobesh@unmc.edu
	Residence:	17459 Karen Street Omaha, Nebraska 68135 Telephone: (402) 614-8044
Date of Birth:		May 30, 1970
Marital Status:		Married June 1, 1996 Stacey L. Dobesh

EDUCATION

Residency

Internal Medicine Specialty Residency
University of Texas / Brackenridge Hospital, Austin, Texas
July 1996 - June 1997
Preceptor: James A. Karboski, Pharm.D.

Doctor of Pharmacy

South Dakota State University, Brookings, South Dakota
Graduated, May 1996

Bachelor of Science in Pharmacy

South Dakota State University, Brookings, South Dakota
Graduated with Honors, May 1994

ACADEMIC / PROFESSIONAL APPOINTMENTS

2015 – Present	Professor of Pharmacy Practice and Science College of Pharmacy University of Nebraska Medical Center Omaha, Nebraska
2005 – Present	Clinical Pharmacy Specialist – Cardiology Nebraska Medicine Omaha, Nebraska
2005 – 2015	Associate Professor of Pharmacy Practice College of Pharmacy University of Nebraska Medical Center Omaha, Nebraska
2003 – 2004	Associate Professor of Pharmacy Practice St. Louis College of Pharmacy St. Louis, Missouri
1997 - 2003	Assistant Professor of Pharmacy Practice St. Louis College of Pharmacy St. Louis, Missouri
1997 - 2004	Clinical Pharmacy Specialist Internal Medicine / Cardiology St. Luke's Hospital Chesterfield, Missouri
1996 - 1997	Clinical Instructor University of Texas College of Pharmacy Austin, Texas
1996 - 1997	Clinical Pharmacy Resident Brackenridge Hospital Austin, Texas
1994 - 1996	Pharmacist Shopko Pharmacy Sioux Falls, South Dakota

TEACHING EXPERIENCE

PHPR 798 Belize Medical Mission Clerkship, UNMC College of Pharmacy

Pharm.D. students on elective rotation

Three to four students in June 2007 – 2009, 2012, 2013, 2016, and 2019

PHPR 730 Adult Cardiology Clerkship, UNMC College of Pharmacy

Pharm.D. student on Level II inpatient rotation

Two to four students for 4 four-week rotation 2005-2022

PHPR 688 Pharmacotherapy III, UNMC College of Pharmacy

Stroke, Spring 2006 – 2012

PHPR 686 Pharmacotherapy II, UNMC College of Pharmacy

Course Coordinator, Spring 2018 – 2022
Cardiology Section Coordinator, Fall 2005 – 2011, Spring 2012 – 2022
Measurement of Vital Signs: Technique and Practice, Fall 2007 – 2009
Hypertension Urgency and Emergency, Fall 2006 – 2011, Spring 2012 – 2022
Chronic Heart Failure, Fall 2005 – 2011, Spring 2012 – 2022
Acute Decompensated Heart Failure and Shock, Spring 2017 – 2022
Ischemic Heart Disease, Fall 2005 – 2011, Spring 2012 - 2022
Venous Thromboembolism, Fall 2005 – 2011, Spring 2012 – 2022
ECG Analysis, Spring 2012 – 2015, 2018 – 2022
Arrhythmias, Fall 2005 – 2011, Spring 2012 – 2022
Peripheral Arterial Disease, Fall 2008 – 2011, Spring 2012 – 2022
Pulmonary Artery Hypertension, Fall 2010 – 2011
Antithrombotic Therapy Pharmacology, Spring 2012 – 2022
Stroke, Spring 2012 – 2022
Chronic Hypertension, Spring 2019

PHPR 672 Pharmacotherapy I, UNMC College of Pharmacy

Blood Products and Reversal of Antithrombotic Agents, Fall 2012 – 2022
Fluid and Electrolytes, Fall 2019 and 2022

Pharm Sci 672 Pharmaceutical Sciences III, UNMC College of Pharmacy

Antiarrhythmics – Clinical Perspective, Spring 2008 – 2022

PHPR 652 Financing Your Future, UNMC College of Pharmacy

Course Coordinator, Fall 2021
Manufacture a Financial Plan, Fall 2021
Protect Your Income, Fall 2021
Eliminate Debt, Fall 2021
Saving for Retirement, Fall 2021

PHPR 622 Drug Literature Evaluation and Research Methods, UNMC College of Pharmacy

Discussion leader, Spring 2005

PHPR 610 Point of Care Testing, UNMC College of Pharmacy

Measurement of Vital Signs and Vital Statistics, Spring 2013 – 2022
Technique Assessment, Spring 2013 – 2022

PHPR 556 Pharmaceutical Care II

Course Coordinator, Spring 2011 – 2022
Patient Interview Skills, Spring 2011 – 2022
Measurement of Vital Signs and Vital Statistics, Spring 2011 – 2022
Cardiology Physical Assessment, Spring 2011 – 2022
Pulmonology Physical Assessment, Spring 2011 – 2022
Ears, Nose, and Throat Physical Assessment, Spring 2011 – 2022
Dermatology Terminology, Spring 2011 – 2022
Neurology Physical Assessment, Spring 2011 – 2022

PHPR 552 Pharmaceutical Care I, UNMC College of Pharmacy

Measurement of Vital Signs and Vital Statistics, Spring 2007 – 2011

PHAS 655 Adult and Pediatric Medicine II for Physician Assistants

Management of Ischemic Heart Disease, Summer 2014 – 2015, Spring 2017 - 2022
Hypertensive Emergencies, Summer 2015 – 2022
Management of Chronic Heart Failure, Spring 2017 - 2022

NU 883 Applied Pharmacology for Advanced Practice Registered Nurses

Pharmacokinetics and Pharmacodynamics, Spring 2008 – 2011
Mechanisms of Drug Interactions, Spring 2008 – 2011
Cardiovascular Pharmacotherapy, Spring 2009 – 2011
Hypertension, Dyslipidemia, Ischemic Heart Disease, Heart Failure, Venous Thromboembolism, and Cardiac Arrhythmias

TH 5002 Therapeutics IV, Saint Louis College of Pharmacy

Course Coordinator, Spring 1999 - 2004
Cardiovascular Risk Reduction, Spring 2000 - 2004.
Physical Assessment Coordinator and Lecturer, Spring 1998 -2004
(topics include: Patient Interview, Blood Pressure and Pulse, Cardiac Exam, Pulmonary Exam, ENT Exam, Dermatology Terminology, and Neurology Exam)
Site Preceptor, Spring 1998 - 2004.

CP 5720 Women's Health Pharmacotherapy, Saint Louis College of Pharmacy

Cardiovascular disease in women, April 2000, 2001.

PP 5100 Pharmacokinetics, Saint Louis College of Pharmacy

Procainamide, Spring 1998 – 2004.
Quinidine, Spring 1998 - 2004.
Lidocaine, Spring 1999 – 2004.
Digoxin, Spring 2002 – 2004.

TH 5001 Therapeutics III, Saint Louis College of Pharmacy

Urinary Tract Infections, Fall 1998.
Arrhythmias, Fall 2004.

TH 4002 Therapeutics II Discussion, Saint Louis College of Pharmacy

Spring 1998, Topics include: Headache, Arthritis, Chronic Obstructive Pulmonary Disease, Asthma, Diabetes Mellitus, Seizure Disorders, Pregnancy and Lactation, and Contraception.

TH 4001 Therapeutics I, Saint Louis College of Pharmacy

Ischemic Heart Disease, Fall 1998 - 2004.
Hypertension, Fall 1998 - 2004.
Heart Failure, Fall 1999 - 2002.
Thromboembolic Disease, Fall 2002 - 2004.
Arrhythmias, Fall 2004.

PP 3100 Pathophysiology, Saint Louis College of Pharmacy

Acute Myocardial Infarction, Spring 1998.
Ischemic Heart Disease, Spring 1998 - 2004.
Acute Coronary Syndromes, Spring 1999 - 2004.
Urinary Tract Infections, Spring 1998, 1999.
Hypertension, Spring 1999 - 2004.
Heart Failure, Spring 2000-2002, 2004.
Venous Thromboembolism, Spring 2002-2004.

School of Occupational Therapy at Maryville University, Chesterfield, MO

Drug Interactions in the Elderly, December 1998 - 2003.

PHR 338 Introduction to Pharmacology, University of Texas at Austin

Depression, November 1996 and March 1997.
Anxiety / Sleep Disorders, November 1996 and March 1997.

Seizure Disorders, November 1996 and March 1997.
Pain Management, November 1996 and March 1997.

PHR 185S Advanced Pharmacotherapy, University of Texas at Austin

Acute Myocardial Infarction Case Discussion, October 1996.
Congestive Heart Failure Case Discussion, September 1996.

PHR 185U Advanced Pharmacotherapy, University of Texas at Austin

Steroids and SLE Case Discussion, February 1997.

PHR 266T Pharmacy Practice Laboratory II, University of Texas at Austin

AbbottBase PKS, August 1996.

Clerkship Preceptor, Saint Louis College of Pharmacy

Pharm.D. students in Internal Medicine and Cardiology, January 1998 – 2004
Two students at a time, 7 of the 9 available rotations a year (average)

Clerkship Preceptor, University of Texas at Austin

B.S. students for Clinical Rotation, February 1997

Student Advising

St. Louis College of Pharmacy: 10 students/year, 1997 – 2004
University of Nebraska Medical Center: 10 students/year, 2005 – 2020

Residency Director for ASHP accredited Internal Medicine Residency at St. Luke's Hospital / St. Louis College of Pharmacy, 2001- 2004.

Cardiology Rotation Primary Preceptor – Nebraska Medical Center Residency Program, 2005 – 2015.

Residents Precepted:

Sheri Alexander, Pharm.D. (5/00)	Nicole Peterson, Pharm.D. (1/09)
Amie McCord, Pharm.D. (9/00)	Jules Felsecker, Pharm.D. (8/09, 1/10)
Michael Boyd, Pharm.D. (1/01)	Greg Peitz, Pharm.D. (1/10)
Jason Enders, Pharm.D.* (7/01 – 6/02)	Jessica Casey, Pharm.D. (8/10 – 9/10)
Gorang Patel, Pharm.D. (11/01)	Allison Baxley, Pharm.D. (10/10 – 11/10)
Julie Brosil, Pharm.D. (1/02)	Sarah Hanigan, Pharm.D. (11/10, 1/11)
Alexander Ansara, Pharm.D.* (7/02 – 6/03)	Rachel King, Pharm.D. (1/11, 4/11)
Paul Walker, Pharm.D. (11/02)	Jamela Urban, Pharm.D. (3/11)
Bethany Lowe, Pharm.D. (4/03)	Craig Reha, Pharm.D. (8/11 – 9/11)
Zachary Stacy, Pharm.D.* (7/03 – 6/04)	Katie Owen, Pharm.D. (10/11)
Shannon Dobson, Pharm.D.* (7/04 – 6/05)	TrisAnn Rendulic, Pharm.D. (11/11)
Russell Roberts, Pharm.D. (11/04)	Kyle Dvoracek, Pharm.D. (1/12)
Jessica Dunn, Pharm.D. (8/05 – 9/05)	Christine Korth, Pharm.D. (8/12 – 9/12)
Jackie Schneider, Pharm.D. (11/05 – 12/05)	Sara Karkanawi, Pharm.D. (11/12)
Jenni Nieman, Pharm.D. (3/06 – 4/06)	Kimberly Karwoski, Pharm.D. (8/13)
Matthew Garr, Pharm.D. (8/06 – 9/06, 4/07)	Megan Austin, Pharm.D. (5/14)
Todd Vaughn, Pharm.D. (2/07)	Beth Gripentrog, Pharm.D. (5/14)
Scott Colman, Pharm.D. (4/07)	Heath Oetken, Pharm.D. (11/14)
April Smith, Pharm.D. (8/07)	Kelsey Aker, Pharm.D. (5/15)
Kimberly Kiniecki, Pharm.D. (10/07)	
Krysta Zack, Pharm.D. (2/08 – 3/08)	
Jill Kestel, Pharm.D. (6/08 – 7/08)	
Tim Hinze, Pharm.D. (8/08)	

* Residency Coordinator

FUNDED RESEARCH

1. *Platelet reactivity with clopidogrel versus prasugrel in patients with systolic heart failure.* Primary investigator, \$98,194 funded, Daiichi Sankyo and Eli Lilly & Co. Alliance. 2012 – 2014.
2. *Impact of clopidogrel exposure in patients with severe sepsis.* Primary investigator, \$15,249 funded, AstraZeneca Pharmaceuticals, 2012 – 2013.
3. *Measurement of Anticoagulant Response with the Thrombelastograph Hemostasis Analyzer System,* Primary investigator, \$58,000, Equipment seed grant from the University of Nebraska Medical Center College of Pharmacy, 2012.
4. *Platelet reactivity and CYP2C19 polymorphisms in American Indians.* Mentor/Co-investigator, \$5000 funded, American College of Clinical Pharmacy Cardiology PRN, 2011 – 2012.
5. *Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation: DESIR-ABLE.* Site principle investigator, \$3780 funded, Canyon Pharmaceuticals, 2010 – 2011.
6. *Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy patients.* Co-investigator, \$3689 funded, Center for Clinical and Translational Research at the University of Nebraska Medical Center, 2010 – 2011.
7. *Impact of ethnicity on platelet function and response to aspirin and clopidogrel.* Mentor/Co-investigator, \$10,000 funded, American Academy of Colleges of Pharmacy, 2010 – 2011.
Effect of statins on LPS response in healthy subjects:
8. *Potential mechanisms of improved survival in patients with sepsis.* Co-investigator, \$71,670 funded, AstraZeneca, January 2009-June 2011.
9. *Potential unrecognized cost of clopidogrel pretreatment in acute coronary syndrome.* Primary investigator, \$5,000 funded, Eli Lilly and Company, 2005.
10. *Utilization of venous thromboembolism prophylaxis in acute medical illness.* Primary investigator, \$3,000 funded, Aventis Pharmaceuticals, 2002.
11. *An evaluation of the safety and efficacy of tirofiban in a community-teaching hospital.* Primary investigator, \$5,000 funded, Merck, 2000.
12. *An evaluation of the safety, efficacy, and compliance with a hospital-specific protocol of abciximab in a community-teaching hospital.* Primary investigator; \$3,000 funded, Eli Lilly and Company, 1999.

ABSTRACT PRESENTATIONS

1. **P.P. Dobesh**, H.L. Brink, M.L. Huntrods, J. Cui, S.M. Sealer. Prevention of catheter complications in patients with cystic fibrosis: enoxaparin vs. a direct oral anticoagulant. **Res Pract Thromb Haemost** 2020;4(Suppl 1):1199:abstract PB2383. Presented as a virtual poster at the XXVIII Congress of the International Society of Thrombosis and Haemostasis, Virtual Meeting, July 2020.
2. **P. Dobesh**, M. Borsh, K. Marth, K. Sorensen, B. Trevarrow. Efficacy and safety of a 4-factor prothrombin complex concentrate for management of direct Xa inhibitor-induced major bleeding. **Res Pract Thromb Haemost** 2019;3:467:abstract PB1489. Presented as a poster at the XXVII Congress of the International Society of Thrombosis and Haemostasis, Melbourne, Australia, July 2019.

3. **P. Dobesh**, K. Sorensen, K. Marth, M. Borsh, B. Trevarrow. A comparison of management strategies for patients with warfarin-induced bleeding. *Res Pract Thromb Haemost* 2019;3:468:abstract PB1491. Presented as a poster at the XXVII Congress of the International Society of Thrombosis and Haemostasis, Melbourne, Australia, July 2019.
4. **P. Dobesh**, K. Marth, M. Borsh, K. Sorensen, B. Trevarrow. Warfarin reversal with a 4-factor prothrombin complex concentrate prior to urgent surgery. *Res Pract Thromb Haemost* 2019;3:468-469:abstract PB1492. Presented as a poster at the XXVII Congress of the International Society of Thrombosis and Haemostasis, Melbourne, Australia, July 2019.
5. **P. Dobesh**, M. Borsh, K. Sorensen, K. Marth, B. Trevarrow. Direct Xa-inhibitor reversal with a 4-factor prothrombin complex concentrate prior to urgent surgery. *Res Pract Thromb Haemost* 2019;3:469:abstract PB1493. Presented as a poster at the XXVII Congress of the International Society of Thrombosis and Haemostasis, Melbourne, Australia, July 2019.
6. Peppard WJ, Mulvey A, Obenberger S, Peppard S, Gibson G, Pape K, Feih J, Huang A, Bialkowski K, Feldman R, Katz M, Fish J, Rolfes K, Herrmann D, Dzierba A, **Dobesh P**. Defining characteristics of “predatory: open access journals in critical care pharmacy practice. *Crit Care Med* 2018;46(12 Suppl 1):Abstract 1053. Presented as a poster at the 48th Annual Critical Care Congress of the Society of Critical Care Medicine. San Diego, CA, January 2019.
7. Cordwin DJ, Daniel K, Klepser DG, **Dobesh PP**. A bedside medication delivery service program reduces 30-day readmissions in patients with cardiac disease. *Circulation* 2018;138(Suppl 1):Abstract 12611. Presented as a poster at the American Heart Association Scientific Sessions 2018. Chicago, IL, November 2018.
8. Cordwin DJ, Klepser DG, **Dobesh PP**. Impact of a bedside medication delivery service on 30-day readmission in cardiology patients. *Pharmacotherapy* 2017. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Phoenix, AZ, October 2017.
9. Wiley TL, **Dobesh PP**, Trevarrow BJ. Management of bleeding complications in patients on oral anticoagulation: a national survey of pharmacists. *Pharmacotherapy* 2017. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Phoenix, AZ, October 2017.
10. **P. Dobesh**, B. Trevarrow, P. Malinowski, K. Guiliano, C. Duncan, K. Gundabolu. Use of a 4-factor prothrombin complex concentrate for management of direct Xa inhibitor-induced major bleeding. *Res Pract Thromb Haemost* 2017;1:934:abstract PD488. Presented as a poster at the XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, July 2017.
11. B. Trevarrow, **P. Dobesh**, M. Wolfe, K. Gundabolu. Use of a 4-factor prothrombin complex concentrate for warfarin reversal prior to urgent surgery. *Res Pract Thromb Haemost* 2017;1:908-909:abstract PB 297 Presented as a poster at the XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, July 2017.
12. **P. Dobesh**, B. Trevarrow, C. Duncan, P. Malinowski, K. Guiliano, K. Gundabolu. A comparison of management strategies for patients with warfarin-induced bleeding. *Res Pract Thromb Haemost* 2017;1:907:abstract PB 294 Presented as a poster at the XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, July 2017.
13. **Dobesh P**, Trevarrow B, Guiliano K, Malinowski P, Duncan C, Gundabolu K. Use of a 4-factor prothrombin complex concentrate for management of warfarin-induced major bleeding. *Crit Care Med* 2016;44(Suppl):abstract 613. Presented as a poster at the 46th Annual Critical Care Congress of the Society of Critical Care Medicine, Honolulu, HI, January 2017.

14. **Dobesh PP.** Use of the platelet aggregation inhibitor ticagrelor in the management of atherothrombotic conditions: overview of the PARTHENON global clinical trial program. <http://www.ashp.org/DocLibrary/Midyear16/Professional-Poster-Listing-by-Primary-Author-Last-Name.pdf>. Presented as a poster the American Society of Health-Systems Pharmacist 2016 Clinical Meeting and Exhibition, Las Vegas, NV, December 2016.
15. **Dobesh P**, Thomas D, Schweitzer A, Louie T, Lowes B, Reha C, Oestreich. Platelet reactivity with clopidogrel versus prasugrel in patients with systolic heart failure. *Pharmacotherapy* 2016;Abstract 33. epage 19 http://www.accp.com/docs/meetings/am16/2016_Annual_Meeting_Abstacts.pdf. Presented as a poster at the 2016 American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 2016.
16. **Dobesh P**, Trevarrow BJ, Varnado SL, Schenk AR, and Rome ET. Use of fibrinolytic therapy in treatment of ventricular assist device thrombosis. *J Thromb Haemost* 2015;13(Suppl S2):116:abstract OR059. Presented as a platform presentation at the XXV International Society on Thrombosis and Haemostasis Congress, Toronto, Canada, June 2015.
17. Dering-Anderson A, **Dobesh PP**, Olsen KM, Klepser DG, Klepser ME, Klepser SA. A rapid diagnostic test certificate program for community pharmacists. Presented as a poster at the CIOMR, Confederation Intralliee des Officiers Medicaux de Reserve (Intrellied Confederation of Medical Reserve Officers) Summer Congress; Fulda/Hammelburg, Germany; August 2014.
18. **Dobesh PP**, McGuire TM, Klepser DG, Himmelberg AL, Roberts DA, Olsen KA. Impact of obesity on outcomes in patients with sepsis. *Crit Care* 2014;18(Suppl 1):S16-S17:abstract 46. Presented at the 35th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 2014.
19. **Dobesh PP**, Klepser DG, McGuire TM, Roberts DA, Himmelberg AL, Olsen KA. Blood product transfusions in septic patients are associated with mortality, ARDS, and more days on mechanical ventilation. *Crit Care* 2014;18(Suppl 1):S38-S39:abstract 111. Presented at the 35th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 2014.
20. Klepser DG, **Dobesh PP**, McGuire TM, Roberts DA, Himmelberg AL, Olsen KA. Does clopidogrel change morbidity and mortality in ICU sepsis patients. *Crit Care* 2014;18(Suppl 1):S85-S86:abstract 238. Presented at the the 35th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 2014.
21. Oestreich JH, Best LG, Crowe BW, and **Dobesh PP**. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in American Indians. *J Thromb Haemost* 2013;11:s2(PB 2.22-6). Presented as a poster at the XXIV International Society on Thrombosis and Haemostasis Congress, Amsterdam, Netherlands, July 2013
22. Dering-Anderson AM, **Dobesh PP**, Klepser DG, Klepser M, Klepser SA, Olsen KM. A Rapid Diagnostic Test Certificate Program for Community Pharmacists. *Am J Pharm Educ* 2013;77(5) Article 109:48. Presented as a poster at the 114th American Association of Colleges of Pharmacy Annual Meeting, Chicago, IL, July 2013
23. **Dobesh P**, Klepser D, McGuire T, Weber J, Schneider S, Olsen K. Transfusions in septic patients are associated with ARDS and increase mechanical ventilation days. *Crit Care Med* 2012;40(Suppl):abstract 1013. Presented as a poster at the 42nd Critical Care Congress of the Society of Critical Care Medicine, San Juan, Puerto Rico, January 2013.
24. **Dobesh P**, Klepser D, McGuire T, Schneider S, Weber J, Olsen K. Impact of clopidogrel exposure on outcomes in patients with sepsis. *Crit Care Med* 2012;40(Suppl):abstract 518. Presented as a poster at the 42nd Critical Care Congress of the Society of Critical Care Medicine, San Juan, Puerto Rico, January 2013.

25. Trevarrow BJ, Purvis-Jeffrey EK, **Dobesh PP**. Reducing heart failure readmissions: a multidisciplinary approach. *Pharmacotherapy* 2012;32:abstract 266, page e256 online at: <http://onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.2012.01219/pdf> Presented as poster at the American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 2012.
26. McGuire TR, **Dobesh PP**, Klepser DG, Kalil AC, Olsen K. Reduction in toll-like receptor-4 (tlr-4) on blood mononuclear cells after 3 weeks of rosuvastatin treatment in healthy male subjects. *Pharmacotherapy* 2012;32:abstract 159, page e224 online at: <http://onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.2012.01219/pdf>. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 2012.
27. **Dobesh PP**, Urban J, Shurmur S, Oestreich J. Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in healthy subjects. *J Am Coll Cardiol* 2012;59(Suppl A):A118 abstract 1160-632. Presented as a poster at the American College of Cardiology 61st Annual Scientific Session, Chicago, IL, March 2012. Presented as an encore poster at the American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 2012. *Pharmacotherapy* 2012;32:abstract 22E, page 184e online at: <http://onlinelibrary.wiley.com/doi/10.1002/j.1875-9114.2012.01219/pdf>
28. **Dobesh P**, Klepser D, McGuire T, Bailey K, Brink H, Schneider S, Weber J, Olsen K. Statins and ACE inhibition in prevention of ARDS. *Crit Care Med* 2011;39(Suppl):abstract 351. Presented as a poster presentation at the 41st Critical Care Congress of the Society of Critical Care Medicine, Houston, TX, February 2012.
29. **Dobesh PP**, Oestreich JH, Hanigan SM, Brink HL, Schneider SM, Weber JM. A comparison of management strategies in patients with acute coronary syndrome based on clopidogrel use. *Pharmacotherapy* 2011;31:abstract 37, page 321e – 322e online at: www.pharmacotherapy.org Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 2011.
30. Oestreich JH, Best LG, **Dobesh PP**. Impact of ethnicity on platelet function and response to aspirin and clopidogrel. *Pharmacotherapy* 2011;75(5) Article 105:144-145. Presented as a poster at the American Association of Colleges of Pharmacy Annual Meeting, San Antonio, TX, July 2011.
31. Reffert JL, **Dobesh PP**, Klepser DG, Collier DS, Olsen KM, Carstens PK. Video-based high-fidelity simulation improves critical care knowledge gain. *Am J Pharm Educ* 2011;75(5) Article 105:66-67. Presented as a poster at the American Association of Colleges of Pharmacy Annual Meeting, San Antonio, TX, July 2011.
32. **Dobesh PP**, Amin A, Klepser DG. VTE prophylaxis in critical care patients: data from VTE START (Venous ThromboEmbolism Study To Assess the Rate of Thromboprophylaxis). *Crit Care Med* 2010;38(Suppl):abstract 12. Presented as a platform presentation at the 40th Critical Care Congress of the Society of Critical Care Medicine, San Diego, CA, January 2011.
33. **Dobesh PP**, Klepser DG, McGuire TR, Hilzeman ML, Olsen KM. ACE inhibition reduces mortality in patients with severe sepsis. *Crit Care Med* 2010;38(Suppl):abstract 422. Presented as a poster presentation at the 40th Critical Care Congress of the Society of Critical Care Medicine, San Diego, CA, January 2011.
34. **Dobesh PP**, Olsen KM, Klepser DG, Carstens PK, Collier DS, Reffert JL. A high-fidelity simulator learning environment improves cardiovascular critical care knowledge gain and retention. *Crit Care Med* 2010;38(Suppl):abstract 493. Presented as a poster presentation at the 40th Critical Care Congress of the Society of Critical Care Medicine, San Diego, CA, January 2011.

35. Bae JP, **Dobesh PP**, Anderson JD, Zagar A, Klepser DG, McCollam PL, Tomlin ME. The effects on dosing complexity on adherence with prescription medications commonly used for cardiovascular patients. *Pharmacotherapy* 2010; abstract #101, page 393e - 394e online at: www.pharmacotherapy.org. Presented as a poster presentation at the American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 2010.
36. Bae JP, **Dobesh PP**, Zagar A, Anderson JD, Tomlin ME, McCollam PL, Klepser DG. An evaluation of once- versus twice-daily dosing on persistence with prescription medications in cardiovascular patients. *Pharmacotherapy* 2010; abstract #102, page 394e online at: www.pharmacotherapy.org. Presented as a poster presentation at the American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 2010.
37. Olsen KM, **Dobesh PP**, Carstens P, Klepser DG, Collier DS. Use of an advanced patient simulator to reinforce instruction of cardiovascular emergencies. *Am J Pharm Educ* 2009;73: Presented as a poster presentation at the 110th Annual Meeting of the American Association of Colleges of Pharmacy, Boston, MA, July 2009.
38. Amin A, Spyropoulos AC, **Dobesh P**, Shorr A, Hussein M, Mozaffari E, Benner JS. Are hospitals delivering quality VTE prevention? The Venous Thromboprophylaxis Study to Assess the Rate of Thromboprophylaxis (VTE START) in the United States. *Blood* 2008;112:Abstract 1286. Presented as a poster at the 50th American Society of Hematology Annual Meeting, San Francisco, CA, December 2008.
39. **Dobesh PP**, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers reduce mortality in septic patients. *Pharmacotherapy* 2008; abstract # 46, page 128e online at: www.pharmacotherapy.org. Presented as a platform presentation at the American College of Clinical Pharmacy Annual Meeting, Louisville, KY, October 2008.
40. Farho LM, **Dobesh PP**. Pharmacy students in Belize. Exposure to cultural competence and social responsibility. *Am J Pharm Educ* 2008;72: Article 72, page 46. Presented as a poster presentation at the 109th Annual Meeting of the American Association of Colleges of Pharmacy, Chicago, IL, July 2008.
41. **Dobesh PP**, Klepser DG, McGuire TR, Morgan CW, Vaughn T, Olsen KM. Statins reduce mortality in septic patients. *Crit Care Med* 2007;35(Suppl):A280. Presented as a poster presentation at the 37th Critical Care Congress of the Society of Critical Care Medicine, Honolulu, HI, February 2008.
42. **Dobesh PP**, Klepser DG. Benefit of clopidogrel therapy beyond 12 months in patients receiving drug-eluting stents. *Pharmacotherapy* 2007; abstract # 15 online at: www.pharmacotherapy.org/pdf/free/ACCP_Abstracts_Fall2007.pdf. Presented as a platform presentation at the American College of Clinical Pharmacy Annual Meeting, Denver, CO, October 2007.
43. Sankaranarayanan J, **Dobesh PP**. Treatment of depression in coronary artery disease: a study of national ambulatory medical care visits from 2000 to 2004. *Value in Health* 2007;10:A48. Presented as a poster at the International Society of Pharmacoeconomics and Outcome Research 12th Annual International Meeting, Arlington, VA, May 2007.
44. **Dobesh PP**, McCollam PL. Potential unrecognized cost of clopidogrel pretreatment in acute coronary syndrome. *Pharmacotherapy* 2005;25:1474. Presented as a platform presentation at the American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 2005. Presented as an encore poster at the 11th annual UNMC Cardiovascular Research Symposium, Omaha, NE, February 2007.

45. Stacy ZA, Dobson SC, **Dobesh PP**. Spironolactone-induced hyperkalemia in patients with heart failure. *Pharmacotherapy* 2005;25:1435-1436. Presented as a platform presentation at the American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 2005.
46. **Dobesh PP**, Stacy ZA. Improvement in quantity and quality of venous thromboembolism prophylaxis for medically ill patients: Impact of a clinical pharmacy education program. *Pharmacotherapy* 2004;24:1475-1476. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Dallas, TX, October 2004.
47. Ansara AJ, **Dobesh PP**, Abu-Shanab JR, Enders JM. Preventing sub-therapeutic anticoagulation with a weight-based heparin nomogram in the treatment of venous thromboembolism. *Pharmacotherapy* 2003;23:1341. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Atlanta, GA, November 2003.
48. Enders JM, **Dobesh PP**. Evaluation of practice patterns in a community hospital based heart failure center: treating heart failure's special populations. *Pharmacotherapy* 2003;23:1330-1331. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Atlanta, GA, November 2003.
49. Enders JM, **Dobesh, PP**, Abu-Shanab JR, Lakamp JE. Utilization of venous thromboembolism prophylaxis in acute medical illness. *Pharmacotherapy* 2002;22:1344. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October 2002.
50. **Dobesh PP**, Schroeder SL, Lakamp JE. Use of acetylcysteine in patients with renal insufficiency prior to cardiac catheterization. *Pharmacotherapy* 2001;21:1259. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Tampa, FL, October 2001.
51. **Dobesh PP**, Abu-Shanab JR, Schroeder SL, Lakamp JE. Outcomes associated with a change in selection of glycoprotein IIb/IIIa agents in a community hospital setting. *Pharmacotherapy* 2000;20:1234. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Los Angeles, CA, November 2000.
52. Schroeder SL, Abu-Shanab JR, **Dobesh PP**, Lakamp JE. Knowledge of hospital acquisition cost of antibiotics among physicians in a community hospital. *Pharmacotherapy* 2000;20:1278. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Los Angeles, CA, November 2000.
53. Holstad S, Burke J, Prosser, **Dobesh P**, Lakamp R. Clinical faculty promotion and tenure guidelines: Models for faculty development. *Am J Pharm Educ* 2000;64(Winter Suppl):92S. Presented as a poster at the American Association of Colleges of Pharmacy Annual Meeting, San Diego, CA, July 2000.
54. Burke J, Prosser T, **Dobesh P**, et al. Teaching faculty to teach: Creating a "Teaching" ability outcome. *Am J Pharm Educ* 2000;64(Winter Suppl):92S-93S. Presented as a poster at the American Association of Colleges of Pharmacy Annual Meeting, San Diego, CA, July 2000.
55. **Dobesh PP**, Maddux MS, Furman GE. An abilities-based approach to teaching physical assessment using standardized patients. *Am J Pharm Educ* 2000;63(suppl):76S. Presented as a poster at the American Association of Colleges of Pharmacy Annual Meeting, Boston, MA, July 1999.
56. Dahdal WY, **Dobesh PP**, Holsted SG, Maddux MS. Practice of professional abilities during introductory practice experiences. *Am J Pharm Educ* 2000;63(suppl):72S. Presented as a poster at the American Association of Colleges of Pharmacy Annual Meeting, Boston, MA, July 1999.

57. **Dobesh PP**, Lakamp JE. Reductions in major bleeding and length of hospitalization following percutaneous coronary interventions with abciximab: Impact of a targeted clinical pharmacy education program. *Pharmacotherapy* 1999;19:1194. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Kansas City, MO, October 1999.
58. **Dobesh PP** and Lakamp JE. Outcomes of abciximab use in patients undergoing percutaneous coronary intervention: preliminary results in the community hospital setting. *Pharmacotherapy* 1999;19:1194. Presented as a poster at the American College of Clinical Pharmacy Annual Meeting, Kansas City, MO, October 1999.

PUBLICATIONS – Textbook Chapters

1. **Dobesh PP**, DiDomenico RJ, Rogers KC. Stable Ischemic Heart Disease. In DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V. *Pharmacotherapy: A Pathophysiologic Approach*. McGraw Hill, 11th edition, 2020. Chapter 32.
2. DiDomenico RJ, **Dobesh PP**, Finks SW. Acute Coronary Syndrome. In DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V. *Pharmacotherapy: A Pathophysiologic Approach*. McGraw Hill, 11th edition, 2020. Chapter 33.
3. **Dobesh, PP**. Anticoagulation in ACCP Updates in Therapeutics: *The Pharmacotherapy Preparatory Course*, American College of Clinical Pharmacy, 2019, 2020, 2021, 2022 ed. Lenexa, KS.
4. **Dobesh, PP**. Anticoagulation in ACCP Updates in Therapeutics: *The Cardiology Pharmacy Preparatory Course*, American College of Clinical Pharmacy, 2018, 2019, 2020, 2021, 2022 ed. Lenexa, KS.
5. **Dobesh PP**, Aker K. Venous thromboembolism prevention. In Dager WE, Gulseth MP, Nutescu EA, editors. *Anticoagulation Therapy: A Clinical Practice Guide*. American Society of Health-System Pharmacists, 2nd edition, 2018, p 283-311.
6. **Dobesh PP**, Stacy ZA. Pharmacology of oral anticoagulants. In Flaker G, editor. *Stroke Prevention in Atrial Fibrillation*. Elsevier, 1st edition, 2018. p. 11-34.
7. **Dobesh PP**. Stable Ischemic Heart Disease. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. *Pharmacotherapy: A Pathophysiologic Approach*. McGraw Hill, 10th edition, 2017. p. 135-163.
8. Stacy ZA, **Dobesh PP**. Management of Acute Coronary Syndrome. In Erstad B, editor. *Critical Care Pharmacotherapy*. American College of Clinical Pharmacy, 1st edition, 2016. p. 660-687.
9. Cook K, **Dobesh PP**. Cardiovascular Disease in Older Adults. *Pharmacotherapy Self-Assessment Program (PSAP)*, American College of Clinical Pharmacy, 7th edition, 2011. p. 27-48.
10. **Dobesh PP**, Stacy ZA. Venous Thromboembolism Prevention. In: Dager WE, Gulseth MP, Nutescu EA. *Anticoagulation Therapy. A Point-Of-Care Guide*. Bethesda: American Society of Health-System Pharmacists; 2011. p. 201-229.
11. **Dobesh PP**. Acute Coronary Syndrome. In: Crouch MA, editor. *Cardiovascular Pharmacotherapy. A Point-Of-Care Guide*. Bethesda: American Society of Health-System Pharmacists; 2010. p. 143-167.
12. **Dobesh PP**, Stacy ZA. Management of chronic stable angina. *Pharmacotherapy Self-Assessment Program (PSAP)*, American College of Clinical Pharmacy, 7th edition, 2010. p. 43-64.

13. **Dobesh PP**, Stacy ZA. Peripheral arterial disease. **Pharmacotherapy Self-Assessment Program (PSAP)**, American College of Clinical Pharmacy, 6th edition, 2007. p. 205-225.
14. **Dobesh P**. Cost-effective drug selection: Antiplatelet agents. In: Becker RC, Harrington RA, editors. **Clinical, Interventional and Investigational Thrombocardiology**. New York: Taylor & Francis; 2005. p. 169-179.
15. **Dobesh PP**. Management of chronic stable angina. **Pharmacotherapy Self-Assessment Program (PSAP)**, American College of Clinical Pharmacy, 5th edition, 2004. p. 237-273.

PUBLICATIONS – Manuscripts in Peer-Reviewed Journals

1. Peppard WJ, Peppard SR, Feih JT, Kim AK, Obenberger SJ, Mulvey AF, Teng BQ, Brazauskas R, Pape, KO, Gibson GA, Dzierba AL, **Dobesh PP**. Prospective observational evaluation of predatory journal in critical care pharmacy practice: defining characteristics associated with receiving unsolicited invitations to publish. **J Pharm Pract** 2021;Oct 13:ahead of press.
2. Beavers CJ, Effoe SA, **Dobesh PP**. Selatogrel: a novel subcutaneous P2Y₁₂ inhibitor. **J Cardiovasc Pharmacol** 2022;79:161-167.
3. Dering-Anderson AM, Mone MA, **Dobesh PP**. When the simulation becomes real. **Am J Pharm Educ** 2022;86;276-279..
4. **The INSPIRATION Investigators**. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. **Thromb Haemost** 2022;122:131-141.
5. **The INSPIRATION Investigators**. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. **JAMA** 2021;325:1620-1630.
6. **Dobesh PP**, Kernan MM, Lueschen JJ. Direct oral anticoagulants in the treatment of venous thromboembolism: use in patients with advanced renal impairment, obesity, or other weight-related special populations. **Semin Respir Crit Care Med** 2021;42:233-249.
7. Coleman CI, **Dobesh PP**, Danese S, Ulloa J, Lovelace B. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. **Future Cardiol** 2021;17:127-135.
8. **Dobesh PP**, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. **Pharmacotherapy** 2020;40:1130-1151.
9. **Dobesh PP**, Finks SW, Trujillo TC. Dual antiplatelet therapy for long-term secondary prevention of atherosclerotic cardiovascular events. **Clin Ther** 2020;42:2084-2097.
10. Cochran GL, Foster JA, Klepser DG, **Dobesh PP**, Dering-Anderson AM. The impact of eliminating backward navigation on computerized exam scores and completion time. **Am J Pharm Educ** 2020;84:1620-1626 (Article 8034).
11. Tomaselli GT, Mahaffey KW, Cuker A, **Dobesh PP**, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker W, Mehran R, Messe SR, Perino AC, Rodriguez F, Sarode R, Siegal D, Wiggins BS. 2020 ACC expert consensus decision pathway on management of bleeding in patients

- on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2020;76:594-622.
12. **Dobesh PP**, Bhatt SH, Trujillo TC, Glaubius K. Antidotes for reversal of direct oral anticoagulants. *Pharmacol Ther* 2019;204:107405.
 13. **Dobesh PP**, Trevarrow BJ. Betrixaban: safely reducing venous thromboembolic events with extended prophylaxis. *Am J Med* 2019;132:307-311.
 14. Trujillo TC, **Dobesh PP**, Crossley GH, Finks SW. Contemporary management of direct oral anticoagulants during cardioversion and ablation for nonvalvular atrial fibrillation. *Pharmacotherapy* 2019;39:94-108.
 15. **Dobesh PP**, Ahuja T, Davis GA, et al. Best practices for implementing venous thromboembolism prophylaxis across the continuum of care. *Am J Manag Care* 2018;24(Suppl 22):S483-S488.
 16. **Dobesh PP**, Ahuja T, Davis GA, et al. The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients. *Am J Manag Care* 2018;24(Suppl 22):S475-S482.
 17. **Dobesh PP**, Ahuja T, Davis GA, et al. Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis. *Am J Manag Care* 2018;24(Suppl 22):S468-S474.
 18. Finks SW, **Dobesh PP**, Trujillo TC, Crossley GH. Periprocedural management of direct oral anticoagulants surrounding cardioversion and invasive electrophysiological procedures. *Cardiol Rev* 2018;26:245-254.
 19. Cave B, Hough A, **Dobesh PP**. Extended venous thromboembolism prophylaxis in medically ill patients. *Pharmacotherapy* 2018;38:597-609.
 20. Tomaselli GT, Mahaffey KW, Cuker A, **Dobesh PP**, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messe SR, Pollack CV, Rodriguez F, Sarode R, Siegal D, Wiggins BS. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. *J Am Coll Cardiol* 2017;70:3042-3067.
 21. Fanikos J, Burnett AE, Mahan CE, **Dobesh PP**. Renal function and direct oral anticoagulant treatment for venous thromboembolism. *Am J Med* 2017;130:1137-1143.
 22. **Dobesh PP**, Patel M. The PARTHENON clinical development program: the role of ticagrelor in patients with atherothrombotic disease. *Cardiovasc Drugs Ther* 2017;31:433-444.
 23. Fanikos J, Burnett AE, Mahan CE, **Dobesh PP**. Renal function considerations for stroke prevention in atrial fibrillation. *Am J Med* 2017;130:1015-1023.
 24. **Dobesh PP**, Fanikos J. Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants: is one of these not like the others? *J Atr Fibrillation* 2016;9:66-74.
 25. Flaker GC, Theriot P, Binder LG, **Dobesh PP**, Cukler A, Doherty JU. Management of periprocedural anticoagulation: a survey of contemporary practice. *J Am Coll Cardiol* 2016;68:217-226.
 26. Finks SW, Trujillo TC, **Dobesh PP**. Management of venous thromboembolism: recent advances in oral anticoagulation therapy. *Ann Pharmacother* 2016;50:486-501.

27. **Dobesh PP**, Varnado S, Doyle M. Antiplatelet agents in cardiology: a report on aspirin, clopidogrel, prasugrel, and ticagrelor. *Curr Pharm Des* 2016;22:1918-1932.
28. Smythe MA, Priziola J, **Dobesh PP**, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. *J Thromb Thrombolysis* 2016;41:165-186.
29. Oliphant CS, Trevarrow BJ, **Dobesh PP**. Clopidogrel response variability: review of the literature and practical considerations. *J Pharm Pract* 2016;29:26-34.
30. **Dobesh PP**, Fanikos J. Direct oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: understanding differences and similarities. *Drugs* 2015;75:1627-1644.
31. Ripley TL, Brenner M, Finks S, Hough A, McConnell KJ, Parker M, **Dobesh PP**. Key articles and guidelines in the management of hypertension: 2015 update. *J Pharm Pract* 2015;28:146-161.
32. **Dobesh PP**, Urban JF, Shurmur SW, Oestreich JH. Impact of a high-fat meal on assessment of clopidogrel-induced platelet inhibition in health subjects. *Thrombosis Journal* 2015;13:3.
33. **Dobesh PP**, Fanikos J. New oral anticoagulants for the treatment of venous thromboembolism: understanding the differences and similarities. *Drugs* 2014;74:2015-2032.
34. **Dobesh PP**, Oestreich JH. Ticagrelor: pharmacokinetic, pharmacodynamics, clinical efficacy, and safety. *Pharmacotherapy* 2014;34:1077-1090.
35. Trujillo T, **Dobesh PP**. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamics rationale for dosing regimens in different indications. *Drugs* 2014;74:1587-1603.
36. **Dobesh PP**, Olsen KM. Statins role in the prevention and treatment of sepsis. *Pharmacol Res* 2014;88:31-40.
37. Oestreich JH, Best LG, **Dobesh PP**. Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. *Am Heart J* 2014;167:413-418.
38. Oestreich JH, **Dobesh PP**. Cangrelor for treatment during percutaneous coronary intervention. *Future Cardiology* 2014;10:201-213.
39. **Dobesh PP**. Economic implications of inadequate treatment of venous thromboembolism and potential solutions. *J Pharm Pract* 2014;27:178-186.
40. McGuire TR, Kalil AC, **Dobesh PP**, Klepser DG, Olsen KM. Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study. *Curr Pharm Des* 2014;20:1156-1160.
41. **Dobesh PP**, Terry KJ. Measuring or monitoring of novel anticoagulants: which laboratory test to request? *Curr Emerg Hosp Med Rep* 2013;1:208-216.
42. **Dobesh PP**, Oestreich JH. Novel direct-acting anticoagulants for risk reduction in ACS. *J Pharm Pract* 2013;26:358-366.
43. **Dobesh PP**, Trujillo TC, Finks SW. Role of the pharmacist in achieving performance measures to improve the prevention and treatment of venous thromboembolism. *Pharmacotherapy* 2013;33:650-664.

44. **Dobesh PP**, Beavers CJ, Herring HR, Spinler SA, Stacy ZA, Trujillo TC. Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention: 2012 update. *Pharmacotherapy* 2012;32:e348-e386.
45. Bae JP, **Dobesh PP**, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, Tomlin ME. Adherence and dosing frequency of common medications for cardiovascular patients. *Am J Manag Care* 2012;18:139-146.
46. Stacy ZA, **Dobesh PP**, Trujillo TC, Dager WE, Ripley T, Olson KL. Key articles and guidelines in the management of peripheral arterial disease. *Pharmacotherapy* 2011;31:176e-206e.
47. Oestreich JH, **Dobesh PP**. Platelet reactivity testing: an objective analysis of current capability. *Acute Coronary Syndromes* 2011;10:55-62.
48. Smith KM, Sorensen T, Connor KA, **Dobesh PP**, Hoehns JD, Marcus KB, Pass SE, Seybert AL, Shapiro NL. Value of conducting pharmacy residency training – The organizational perspective. *Pharmacotherapy* 2010;30:490e-510e.
49. **Dobesh PP**. The importance of prophylaxis for the prevention of venous thromboembolism in at-risk medical patients. *Int J Clin Pract* 2010;64:1554-1562.
50. **Dobesh PP**, Trujillo. Anticoagulation in the management of ST-segment elevation myocardial infarction. *J Pharm Pract* 2010;23:335-343.
51. **Dobesh PP**, Trujillo. Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome. *J Pharm Pract* 2010;23:324-334.
52. Amin A, Spyropoulos AC, **Dobesh P**, Shorr A, Hussein M, Mozaffari E, Benner JS. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE START). *J Thromb Thrombolysis* 2010;29:326-339.
53. **Dobesh PP**, Swahn SM, Peterson EJ, Olsen KM. Statins in sepsis. *J Pharm Pract* 2010;23:38-49.
54. **Dobesh PP**. Clopidogrel versus prasugrel: times are changing, but not for everyone. *Pharmacotherapy* 2009;29:1393-1396.
55. **Dobesh PP**, Wittkowsky AK, Stacy Z, Dager WE, Trujillo TC, Gulseth MP, Nutescu E, Vondracek T. Key articles and guidelines in the treatment of venous thromboembolism. *Pharmacotherapy* 2009;29:293e-338e.
56. Bae JP, **Dobesh PP**, McCollam PL, Khoynezhad A. Potential unrecognized costs of clopidogrel pretreatment in acute coronary syndrome. *J Med Econ* 2009;12:325-330.
57. McGuire T, **Dobesh P**, Klepser D, Rupp M, Olsen K. Clinically important interaction between statin drugs and *Clostridium difficile* toxin? *Medical Hypotheses* 2009;73:1045-1047.
58. **Dobesh PP**. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. *Pharmacotherapy* 2009;29:1089-1102.
59. **Dobesh PP**. Economic burden of venous thromboembolism in hospitalized patients. *Pharmacotherapy* 2009;29:943-953.
60. **Dobesh PP**, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Reduction in mortality associated with statin therapy in patients with severe sepsis. *Pharmacotherapy* 2009;29:621-630.

61. **Dobesh PP**, Stacy ZA, Persson EL. Pharmacologic therapy for intermittent claudication. *Pharmacotherapy* 2009;29:526-553.
62. **Dobesh PP**, Wittkowsky AK, Stacy Z, Dager WE, Haines ST, Lopez LM, Nutescu E, Phillips KW, Trujillo TC, Vondracek T. Key articles and guidelines for the prevention of venous thromboembolism. *Pharmacotherapy* 2009;29:410-458.
63. **Dobesh PP**, Phillips KW, Haines ST. Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. *Am J Health-Syst Pharm* 2008;65(Suppl 7):S22-S28.
64. Phillips KW, **Dobesh PP**, Haines ST. Considerations in using anticoagulant therapy in special patient populations. *Am J Health-Syst Pharm* 2008;65(Suppl 7):S13-S21.
65. **Dobesh PP**, Phillips KW, Haines ST. Improving the use of anticoagulant therapies in acutely ill medical patients. *Am J Health-Syst Pharm* 2008;65(Suppl 7):S5-S12.
66. Khoynezhad A, **Dobesh PP**, Stacy Z, Jalali Z. The role of intravenous dihydropyridine calcium channel blockers in the perioperative management of patients undergoing coronary artery bypass surgery. *Curr Vasc Pharmacol* 2008;6:186-194.
67. **Dobesh PP**, Brouse SD, Dager WE, Spinler SA, Stacy ZA, Wiggins BS. Key articles and guidelines in the management of acute coronary syndrome and in percutaneous coronary intervention – 2007 update. *Pharmacotherapy* 2007;27:1722-1758.
68. Trujillo TC, **Dobesh PP**. Traditional management of chronic stable angina. *Pharmacotherapy* 2007;27:1677-1692.
69. **Dobesh PP**, Trujillo TC. Ranolazine: A new option in the management of chronic stable angina. *Pharmacotherapy* 2007;27:1659-1676.
70. **Dobesh PP**. Stable angina: current state of disease management. *J Manag Care Pharm* 2006;12:S4-S9.
71. Nutescu EA, Wittkowsky AK, **Dobesh PP**, Hawkins DW, Dager WE. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach. *Ann Pharmacother* 2006;40:1558-1571.
72. **Dobesh PP**, Bosso, J, Wortman S, Dager WE, Karpiuk EL, Ma Q, Zarowitz BJ. Clinical pathways: the role of pharmacy today and tomorrow. *Pharmacotherapy* 2006;26:1358-1368.
73. Stacy ZA, **Dobesh PP**, Trujillo TC. Cardiovascular risks of cyclooxygenase inhibition. *Pharmacotherapy* 2006;26:919-938.
74. **Dobesh PP**. Managing hypertension in patients with type 2 diabetes mellitus. *Am J Health-Syst Pharm* 2006;63:1140-1149.
75. Murphy JE, Nappi JM, Bosso JA, Saseen JJ, Hemstreet BA, Halloran MA, Spinler SA, Welty TE, **Dobesh PP**, Chan L-N, Garvin CG, Grunwald PE, Kamper CA, Sanoski CA, Witkowski PL. American College of Clinical Pharmacy's vision of the future: postgraduate pharmacy residency training as a prerequisite for direct patient care practice. ACCP Position Statement. *Pharmacotherapy* 2006;26:722-733.
76. **Dobesh PP**, Stacy ZA. Improvement in quantity and quality of venous thromboembolism prophylaxis for medically ill patients: impact of a clinical pharmacy education program. *J Manag Care Pharm* 2005;11:755-762.

77. Spinler SA, **Dobesh PP**. Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. (letter). *CHEST*. 2005;127:2288-2289.
78. **Dobesh PP**, Stacy ZA, Ansara AJ, Enders JE. Drug-eluting stents: a mechanical and pharmacological approach to coronary artery disease. *Pharmacotherapy* 2004;24:1554-1577.
79. **Dobesh PP**. Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics. *Pharmacotherapy* 2004;24:169S-178S.
80. **Dobesh PP**, Kim K, Stacy Z. The future of anticoagulation. *J Pharm Pract* 2004;17:370-384.
81. McGuire M, **Dobesh PP**. Therapeutic update on the prevention and treatment of venous thromboembolism. *J Pharm Pract* 2004;17:289-307. (Erratum published in *J Pharm Pract* 2005;18:132.)
82. **Dobesh PP**. Unfractionated heparin dosing nomograms: roadmaps to where? *Pharmacotherapy* 2004;24:142S-145S.
83. **Dobesh PP**. Economics of unfractionated heparin: beyond acquisition cost. *Pharmacotherapy* 2004;24:161S-164S.
84. **Dobesh PP**. Evidence for extended prophylaxis in the setting of orthopedic surgery. *Pharmacotherapy* 2004;24:73S-81S.
85. **Dobesh PP**, Brouse SD, Johnson DC, Dager WE, Bell D, Daly DE, Olin JL, Wodlinger AM. Key articles and guidelines relative to the management of patients with acute coronary syndromes. *Pharmacotherapy* 2004;24:105-144.
86. Enders JM, **Dobesh PP**, Ellison JN. Acute myocardial infarction induced by ephedrine alkaloids. *Pharmacotherapy* 2003;23:1645-1651.
87. **Dobesh PP**. Novel concepts: emerging data and the role of extended prophylaxis following hip fracture surgery. *Am J Health-Syst Pharm* 2003;60(Suppl 7):S15-19.
88. **Dobesh PP**, Lanfear SL, Abu-Shanab JR, Lakamp JE, Gowda G, Haikal M. Outcomes associated with a change in prescribing of glycoprotein IIb/IIIa inhibitors in percutaneous intervention in a community hospital setting. *Ann Pharmacother* 2003;37:1375-1380.
89. Enders JM, Burke JM, **Dobesh PP**. Prevention of venous thromboembolism in acute medical illness. *Pharmacotherapy* 2002;22:1564-1578.
90. **Dobesh PP**, Lakamp JE. Educational program to reduce major bleeding in patients undergoing percutaneous coronary interventions and receiving abciximab. *Am J Health-Syst Pharm* 2002;59:1539-1542.
91. Schroeder SL, **Dobesh PP**, Abu-Shanab JR, Lakamp JE. Knowledge of hospital acquisition cost of antibiotics among physicians in a community hospital. *Hosp Pharm*. 2002;37:833-839.
92. **Dobesh PP**, Kasiar JB. Administration of glycoprotein IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction. *Pharmacotherapy*. 2002;22:864-888.
93. Lakamp JE, **Dobesh PP**. Propofol and too much sulfite? (letter) *CHEST*. 2000;118:277.
94. **Dobesh PP**, Latham KA. Advancing the battle against acute ischemic syndromes: A focus on the GP IIb/IIIa inhibitors. *Pharmacotherapy*. 1998;18:663-685.

PUBLICATIONS – Manuscripts in Non-Peer-Reviewed Journals

1. **Dobesh PP.** Pharmacist-led transitions of care: improving outcomes for extended thromboprophylaxis in high risk medically ill patients. **Power-Pak CE.** Available at: <https://www.powerpak.com/course/preamble/121388>. Accessed December 31, 2021.
2. **Dobesh PP.** DOACs for bioprosthetic mitral valves – finally some real data. **Nebraska ACC Newsletter.** 2021;2:4
3. **Dobesh PP.** Chronic CAD and PAD: reducing major adverse cardiovascular events with dual pathway inhibition antithrombotic therapy. **Pharmacy Times** 2020;86:86-100.
4. **Dobesh PP, Mahan CE.** Straight to the source: top questions hospital pharmacists will receive about reversal of factor Xa inhibitors. **Power-Pak CE.** Available at: <https://www.powerpak.com/course/preamble/118890>. Accessed December 31, 2019
5. **Dobesh PP.** SPIRIT IV: New evidence the everolimus (XIENCE V®) drug eluting stent (DES) is superior to other DES at least in some patient groups, but questions remain. **ClotCare Online Resource,** http://www.clotcare.org/spirit_iv_drug_eluting_stents.aspx. November 2010.
6. Dager WE, **Dobesh PP.** Risk-directed management of the patient with acute coronary syndrome: optimizing antiplatelet therapy. **Pharmacy Practice News** 2008;October 1:1-8.
7. **Dobesh, PP.** Why is there a need for protocols? **Adv Stud Pharm** 2007;4:181-187.
8. Chase SL, **Dobesh PP,** Gibson GA, Spinler SA. Pharmacologic considerations in acute coronary syndrome (ACS): an expert debate. **P&T** 2007;32:2-18.
9. **Dobesh PP.** Enoxaparin appears as effective as unfractionated heparin for people with high risk non-ST elevation acute coronary syndromes receiving rapid invasive therapy – Commentary. **Evid Based Cardiovasc Med** 2005;9:180-183.
10. Stacy ZA, **Dobesh PP.** The future of stroke prevention in atrial fibrillation. **Cardiology Today** 2004;7:28.
11. **Dobesh PP.** Options in the prophylaxis of medical patients. **MCConsultant** 2003;3:19-24.
12. **Dobesh PP,** Enders J. Amiodarone: the new standard in VF treatment. **Cardiology Today.** 2002;5:30.
13. Spinler SA, Bosker G, Brady WJ, Cheng J, **Dobesh PP,** Emerman CL, Kleinschmidt K, Nappi J, Pieper J, Sarembock IJ, Stringer KA, Talbert R, Volturo G, Wittkowsky A. Acute myocardial infarction and coronary syndromes: optimizing selection of reperfusion and revascularization therapies in the coronary care unit (CCU) and emergency department. CTAP Consensus Panel Report and Scientific Roundtable. **Hospital Pharmacist Consensus Report.** 2001;December:1-24.

INVITED PRESENTATIONS

International Meetings

1. *Dosing and Monitoring Considerations with Direct Oral Anticoagulants*. Grand rounds presentation at Nanfang Hospital, Guangzhou, China, November 2018.
2. *Dosing and Monitoring Considerations with Direct Oral Anticoagulants*. Grand rounds presentation at Fujian Medical University, Fuzhou, China, November 2018.
3. *Dosing and Monitoring Considerations with Direct Oral Anticoagulants*. Grand rounds presentation at Anhui Medical University, Hefei, China, October 2018.
4. *Ambulatory Care in Cardiology – Stable Angina: An Update*. Presented at the 3rd International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, April 2015.
5. *Venous Thromboembolism (VTE) Challenge – VTE: Acute and Chronic Management*. Presented at the 3rd International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, April 2015.
6. *Evolution of Anti-Platelet Therapy Use in Cardiovascular Disease – Optimizing Duration of Antiplatelet Therapy Following Acute Coronary Syndrome*. Presented at the 3rd International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, April 2015.
7. *Optimizing the Clinical Management of Acute Coronary Syndrome (ACS) – Antiplatelet Strategies in Acute Coronary Syndrome: Expanding Options*. Presented at the 3rd International Cardiovascular Pharmacotherapy Conference, Riyadh, Saudi Arabia, April 2015.
8. *Antiplatelet Unresponsiveness: Genomic Markers and Advanced Testing*. Presented at the 2nd International Cardiovascular Pharmacology Conference, Riyadh, Saudi Arabia, April 2012.
9. *VTE: Acute and Chronic Management*. Presented at the 2nd International Cardiovascular Pharmacology Conference, Riyadh, Saudi Arabia, April 2012.
10. *Atrial Fibrillation*. Moderator of session at the 2nd International Cardiovascular Pharmacology Conference, Riyadh, Saudi Arabia, April 2012.
11. *Cardiovascular Physical Examination*. Presented as a workshop at the 2nd International Cardiovascular Pharmacology Conference, Riyadh, Saudi Arabia, April 2012.
12. *Anticoagulation in ACS and Beyond*. Presented at the 2nd International Cardiovascular Pharmacology Conference, Riyadh, Saudi Arabia, April 2012.
13. *Antiplatelet Strategies in Acute Coronary Syndrome: Expanding Choices*. Presented at the 2nd International Cardiovascular Pharmacology Conference, Riyadh, Saudi Arabia, April 2012.
14. *Drug Eluting Stents in PCI: Assessing the Risks and Benefits*. Noon conference presented to physicians, pharmacists, and nurses at Changi General Hospital, Singapore, July 2011.
15. *New Anticoagulant and Antiplatelet Agents*. Noon conference presented to cardiologist, pharmacists, and nurses at Changi General Hospital, Singapore, July 2011.
16. *Antithrombotic Therapy in the Management of Acute Coronary Syndrome: A Practical and Evidence-Based Approach*. Grand rounds presentation at Changi General Hospital, Singapore, July 2011.
17. *VTE Prevention in Orthopedic Surgery Patients*. Grand rounds presentation to the Khoo Teck Puat Hospital surgery department, Khoo Teck Puat Hospital, Singapore, July 2011.
18. *Incorporating Guidelines into Clinical Practice – Anticoagulant and Antiplatelet Therapy in Patients with NSTEMI ACS*. Presented to pharmacists at Khoo Teck Puat Hospital, Singapore, July 2011.

19. *Incorporating Guidelines into Clinical Practice – Anticoagulant and Antiplatelet Therapy in Patients with STEMI.* Presented to pharmacists at Khoo Teck Puat Hospital, Singapore, July 2011.
20. *Management of Arrhythmias in the Emergency Setting and Selection of Antiarrhythmic Agents.* Grand rounds lecture presented to emergency department physicians, pharmacists, and nurses at Khoo Teck Puat Hospital, Singapore, July 2011.
21. *Venous Thromboembolism Prophylaxis: Can We Do Better?* Presented at the Clinical Forum at Khoo Teck Puat Hospital, Singapore, July 2011.
22. *Peripheral Artery Disease.* Presented to pharmacists at Tan Tock Seng Hospital, Singapore, July 2011.
23. *VTE Prevention in Medically Ill Patients.* Noon conference presentation to cardiologists and pharmacists at Khoo Teck Puat Hospital, Singapore, July 2011.
24. *Acute Decompensated Heart Failure: Controversies, Guidelines, and Future Directions.* Grand rounds presentation at Tan Tock Seng Hospital, Singapore, July 2011.
25. *Pulmonary Arterial Hypertension.* Presented to physicians, pharmacists, and nurses at National University Hospital, Singapore, July 2011.
26. *Anticoagulation in Special Populations.* Presented to physicians, pharmacists, and nurses at National University Hospital, Singapore, July 2011.
27. *Switching Between P2Y₁₂ Inhibitors – What's the Evidence?* Cardiology noon conference presented at National University Hospital, Singapore, July 2011.
28. *Heparin Induced Thrombocytopenia.* Grand rounds presentation to pharmacists at National University Hospital, Singapore, July 2011.
29. *Management of Chronic Heart Failure.* Presented at the 21st Annual Singapore Pharmacy Congress, Singapore, July 2011.
30. *Cardiology Workshop – Electrocardiogram Analysis, Cardiac Physical Assessment, and Case Studies.* Presented at the 21st Annual Singapore Pharmacy Congress, Singapore, July 2011.
31. *Antiplatelet Nonresponsiveness, Treatment, and Future Directions.* Presented to the Pharmaceutical Society of Singapore, Singapore, July 2011.
32. *Role of Glycoprotein IIb/IIIa Inhibitors with Heparin/Low-Molecular Weight Heparin versus Bivalirudin in ACS.* Presented to physicians and pharmacists at Khoo Teck Puat Hospital, Singapore, July 2011.
33. *Treatment of Atrial Fibrillation and PSVT.* Noon conference presentation to medical residents and students. Jurong General Hospital, Singapore, July 2011.
34. *New Anticoagulants.* Grand rounds presentation to physicians, nurses, and pharmacists at Jurong General Hospital, Singapore, July 2011.
35. *New Anticoagulants.* Presented to physicians, nurses, and pharmacists at Khoo Teck Puat Hospital, Singapore, July 2011.
36. *Drug-Eluting Stent Technology.* Presented to cardiologists and pharmacists at Khoo Teck Puat Hospital, Singapore, July 2011.

37. *Stepwise Evaluation and Management of Acute Coronary Syndrome*. Presented at the 1st International Cardiovascular Pharmacology Conference – Emerging Insights into Cardiovascular Pharmacotherapy, Riyadh, Saudi Arabia, January 2010.
38. *Antithrombotic Therapy in the Management of Acute Coronary Syndrome: A Practical and Evidence-Based Approach*. Presented at the 1st International Cardiovascular Pharmacology Conference – Emerging Insights into Cardiovascular Pharmacotherapy, Riyadh, Saudi Arabia, January 2010.
39. *Drug Eluting Stents in PCI: Assessing the Risks and Benefits*. Presented at the 1st International Cardiovascular Pharmacology Conference – Emerging Insights into Cardiovascular Pharmacotherapy, Riyadh, Saudi Arabia, January 2010.
40. *Venous Thromboembolism*. Moderator of session at the 1st International Cardiovascular Pharmacology Conference – Emerging Insights into Cardiovascular Pharmacotherapy, Riyadh, Saudi Arabia, January 2010.
41. *Ambulatory Care Cardiology – Stable Angina: Newer Agents and Maximal Drug Therapy*. Presented at the 1st International Cardiovascular Pharmacology Conference – Emerging Insights into Cardiovascular Pharmacotherapy, Riyadh, Saudi Arabia, January 2010.
42. *Advances in Anticoagulation in Cardiology*. Presented at the Middle East College of Clinical Pharmacy Lebanese American University 2nd Intl Clinical Conference, Byblos, Lebanon, May 2004.

National Meetings

1. *Anticoagulation Management*. Presented at the Pharmacotherapy Preparatory Review Course, St. Louis, MO, April 2022.
2. *Currant Approaches to Antiplatelet Therapy for PCI in ACS & SIHD: Debate Pro: Challenging the Status Quo; Contemporary Trials in Favor of SAPT in ACS*. Presented at the American College of Cardiology 71st Annual Scientific Session & Expo, Washington DC, April 2022.
3. *Anticoagulation Management*. Presented at the Pharmacotherapy Preparatory Review Course, Virtual Conference, April 2021.
4. *The ABCs of Cardiology in 2020: Antiplatelets to Anticoagulation: Best Practices in Antiplatelet and Anticoagulant Therapy: When Less is More? Triple vs. Double Antithrombotic Therapy*. Presented at the Cardiology PRN Focus Session at the American College of Clinical Pharmacy Annual Meeting, Virtual Conference, October 2020.
5. *Cardiovascular Professionals Symposium: Antithrombotic Pharmacology – Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding*. Presented at the Society of Cardiovascular Angiography and Interventions Scientific Sessions, Virtual Conference, May 2020.
6. *Anticoagulation Management*. Presented at the Pharmacotherapy Preparatory Review Course, Virtual Conference, April 2020.
7. *Oral Anticoagulant Reversal Agents: Deconstructing the Clinical Data*. Presented as a satellite symposium at the 54th American Society of Health Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2019.
8. *Anticoagulation vs. Aspirin for VTE Prophylaxis Following Orthopedic Surgery – Pro Anticoagulation*. Presented at the Adult Medicine PRN Focus Session at the American College of Clinical Pharmacy Annual Meeting, New York, NY, October 2019.

9. *Anticoagulation Management*. Presented at the Pharmacotherapy Preparatory Review Course, St. Louis, MO, April 2019.
10. *Updates in Antiplatelet Management*. Session panelist at the American College of Cardiology 68th Annual Scientific Sessions & Expo, New Orleans, LA, March 2019.
11. *Therapeutic Challenges: Direct Oral Anticoagulants in Special Populations*. Presented at the 53rd American Society of Health Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2018.
12. *Management of Peripheral Arterial Disease*. Presented at the 33rd Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT) – Challenges and Controversies in Antithrombotic Therapy. Anaheim, CA, December 2018.
13. *Anticoagulation Management*. Presented at the Cardiology Pharmacy Preparatory Review Course, Pomona, CA, April 2018
14. *Stable Ischemic Heart Disease*. Presented at the Cardiology Pharmacy Preparatory Review Course, Pomona, CA, April 2018.
15. *Coagulopathies in Trauma: From Hemostatic Resuscitation to the Reversal of Novel Oral Anticoagulant – Management and Reversal of Acute Traumatic Coagulopathy and Direct Oral Anticoagulants*. Presented at the Society of Critical Care Medicine 47th Critical Care Congress in San Antonio, TX, February 2018.
16. *Anticoagulation*. Presented at the Cardiology Pharmacy Preparatory Review Course, Jacksonville, FL, February 2018.
17. *Arterial Disease and Oral Anticoagulation*. Presented at the 32nd Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT) – Challenges and Controversies in Antithrombotic Therapy. Orlando, FL, December 2017.
18. *Preventing Venous Thromboembolism in Acutely Ill Patients: Key Considerations for Pharmacists*. Presented as a breakfast symposium at the 52nd American Society of Health Systems Pharmacists Midyear Clinical Meeting. Orlando, FL, December 2017.
19. *Expanding Pharm Tech Roles: Measuring Vital Signs*. Presented at the American Association of Pharmacy Technicians 35th Annual National Convention, Omaha, NE, August 2017.
20. *What in the World? The UFOs of EP Practice – Choosing a Novel Oral Anticoagulant for Your Patient? The NOAC Conundrum*. Presented at the Heart Rhythm Society Scientific Sessions. Chicago, IL, May 2017.
21. *Anticoagulation Reversal Agents: What's the Latest and Greatest?* Presented at the American College of Cardiology 66th Annual Scientific Sessions & Expo, Washington DC, March 2017.
22. *Ask the Experts: An Update on the Management of Myocardial Infarction and Venous Thromboembolism*. Presented at the American Pharmacists Association 2017 Annual Meeting and Exposition, San Francisco, CA, March 2017.
23. *From Clots to Cor Pulmonale – Evidence-Based Options for the Management of Venous Thromboembolism*. Presented at the American College of Cardiology 65th Annual Scientific Session & Expo, Chicago, IL, April 2016.

24. *Contemporary Clinical Controversies Involving Anticoagulation in Atrial Fibrillation – Pharmacology Program III*. Presented at the American College of Cardiology 65th Annual Scientific Session & Expo, Chicago, IL, April 2016.
25. *Smoothing the Path Home: Managing Transitions of Care for Patients with Acute Coronary Syndrome*. Presented at the American Pharmacists Association 2016 Annual Meeting and Exposition. Baltimore, MD, March 2016.
26. *Expert Debate: Novel Oral Anticoagulants*. Moderated and presented at the American Pharmacists Association 2016 Annual Meeting and Exposition, Baltimore, MD, March 2016.
27. *Cardiovascular Guideline Hot Potato: Catching the Key Updates and Recommendations NSTEMI ACS Guideline Update*. Presented at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2015.
28. *Nonwarfarin Oral Anticoagulants (NOACs): The Clinical Pharmacist's Perspective*. Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2015.
29. *Advances in the Pharmacotherapy of Cardiovascular Diseases: Optimal Duration of Dual Antiplatelet Therapy for Management of Coronary Artery Disease*. Presented at the American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 2015.
30. *Making Bloody Sense of Antithrombotic Therapy during Percutaneous Coronary Intervention: A New Champion? Exploring the Potential of Cangrelor in Patients Undergoing Percutaneous Coronary Intervention*. Presented as part of the Cardiology PRN Focus Session at the American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 2015.
31. *Improving Adherence to Optimal Medical Therapy*. Presented at the American College of Cardiology 64th Annual Scientific Sessions and Expo, San Diego, CA, March 2015.
32. *An Overview of Advances in Anticoagulation Therapy*. Presented at the American Pharmacists Association 2015 Annual Meeting and Exposition, San Diego, CA, March 2015.
33. *Optimizing the Management of Acute Coronary Syndromes Through Transitions of Care*. Presented at the American Pharmacists Association 2015 Annual Meeting and Exposition, San Diego, CA, March 2015.
34. *Overcoming Challenges in Acute Coronary Syndrome – Clopidogrel Nonresponsiveness: What Does it Mean to You?* Chaired and presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2014.
35. *Riding the Waves in Pharmacy ACS Management: Surfing Across the Continuum of Care – The Role of Antiplatelet Therapy in the Treatment of Secondary Prevention of Acute Coronary Syndrome*. Chaired and presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2014.
36. *Treatment of VTE with the Newer Target Specific Oral Anticoagulants*. Presented at the 29th Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT) – Challenges and Controversies in Antithrombotic Therapy. Anaheim, CA, December 2014.
37. *Pharmacology Program I – What's New with the New Oral Anticoagulants*. Presented at the American College of Cardiology 63rd Annual Scientific Sessions and Expo, Washington DC, March 2014.

38. *Advances in Anticoagulation Therapy*. Presented at the American Pharmacists Association 2014 Annual Meeting and Exposition, Orlando, FL, March 2014.
39. *Thrombosis, Antithrombotic Prophylaxis and Therapy in Pediatric Heart Disease – Pharmacogenomics of Aspirin and Warfarin in Children*. Presented at the American Heart Association Scientific Sessions 2013, Dallas, TX, November 2013.
40. *High-Risk Patients and High-Risk Medications: Role of the Cardiovascular Clinical Pharmacist – Cardiology PRN Focus Session*. Moderated session at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October 2013.
41. *Challenges in Drug Dosing for Complicated Patient Populations – Anticoagulants in Special Populations: Challenges in the Pregnant and Post-Partum Populations – Anticoagulation*. Presented as part of curricular track 1 at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October 2013.
42. *Promoting an Effective Transition to Community-Based Care in Acute Coronary Syndromes: Pathways to Success – Advances in the Treatment and Secondary Prevention of Acute Coronary Syndromes*. Chaired and presented as a satellite symposium at the American Pharmacist Association's 2013 Annual Meeting, Los Angeles, CA, March 2013.
43. *The Pharmacist Role in ACS Management: Translating Data into Practice - ACS from A to Z: Advances in Pathophysiology and Treatment and Current Issues for the Pharmacist*. Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2012.
44. *Traveling Optimal Pathways for Managing Stable Ischemic Heart Disease – Optimal Medical Therapy (OMT) for Stable Ischemic Heart Disease: Improving Prognosis*. Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2012.
45. *Measuring vs. Monitoring Newer Antithrombotic Agents*. Presented at the 27th Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT) – Evidence-Based ACCP Guidelines 2012 and Novel Antithrombotic therapy: Practice Transformation for the Pharmacist, Las Vegas, NV, December 2012.
46. *Implementing the AT9 in Clinical Practice*. Part of a panel discussion at the 27th Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT) – Evidence-Based ACCP Guidelines 2012 and Novel Antithrombotic therapy: Practice Transformation for the Pharmacist, Las Vegas, NV, December 2012.
47. *The Pharmacist Role in ACS Management: Translating Data into Practice - ACS from A to Z: Advances in Pathophysiology and Treatment and Current Issues for the Pharmacist*. Presented as a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 2012.
48. *Pharmacology Program: Pharmacologic Considerations in the Setting of PCI*. Panel discussion conducted at the American College of Cardiology 61st Annual Scientific Sessions & Expo. Chicago, IL, March 2012.
49. *Antithrombotic Therapeutic Pearls and Debates 2011: New Insights into a New World – Therapeutic Debate: Which New Agent is Better for Prophylaxis of VTE? Support for Rivaroxaban*. Presented at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2011.

50. *Oral Antithrombotic Therapy – Laboratory Monitoring and Special Considerations.* Presented as part of the Clinical Reasoning Series – From Theory to Bedside at the American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 2011.
51. *Oral Antithrombotic Therapy – The Science of Antithrombotic Agents-Therapeutic Implications.* Presented as part of the Clinical Reasoning Series – From Theory to Bedside at the American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 2011.
52. *Antiplatelet Therapy in the Modern Era: Non-Responsiveness, Treatment, and Future Directions – Clinical Implications of Antiplatelet Non-Responsiveness.* Presented at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010.
53. *Optimizing Oral Antiplatelet Therapy in Acute Coronary Syndrome – Emerging Treatment Strategies.* Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010.
54. *Debates and Pearls in Antithrombotic Therapy: Practical Insights for Patient Care – Therapeutic Debate: What is the Appropriate Heparin Regimen for DVT Prophylaxis in the Medically Ill, 5000 Units Subcutaneously Q8H or Q12H? Support for UFH Q8H.* Presented at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010.
55. *Improving the Prevention and Treatment of Venous Thromboembolism in Cancer: The Strategic Role of the Health-System Pharmacist – Case Scenarios: Newly Studied and Emerging Approaches to the Management of VTE in Cancer.* Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2010.
56. *Emerging Anticoagulants and Antithrombotics – Arterial Thrombosis.* Presented at the American Pharmacists Association 2010 Annual Meeting & Exposition, Washington DC, March 2010.
57. *Acute Coronary Syndrome: New Treatment Options.* Presented at the American Pharmacists Association 2010 Annual Meeting & Exposition, Washington DC, March 2010.
58. *Guidelines for Anticoagulant and Antiplatelet Therapy in the Management of Acute Coronary Syndrome: Incorporation into Clinical Practice – Guidelines for Anticoagulant and Antiplatelet Therapy in Patients with STEMI.* Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, FL, December 2008.
59. *Guidelines for Anticoagulant and Antiplatelet Therapy in the Management of Acute Coronary Syndrome: Incorporation into Clinical Practice – Guidelines for Anticoagulant and Antiplatelet Therapy in Patients with NSTEMI ACS.* Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, FL, December 2008.
60. *Controversies in the Management of ACS and VTE. 2008 Educational Initiative on Improving Patient Outcomes in Thromboembolic Disorders.* Presented at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, FL, December 2008.
61. *Guidelines for Anticoagulant Therapy in the Prevention and Treatment of Venous Thromboembolism: Achieving Meaningful Quality Improvement – Guidelines for Antithrombotic Therapy in Patients at Risk for VTE.* Presented at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, FL, December 2008.
62. *The Impact of Age on the Choice of Antiplatelet Therapy – Current and Future Antiplatelet Treatment Options for Risk Reduction.* Presented as a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, Louisville, KY, October 2008.

63. *Tools to Become More Effective in Scholarly Activity – Writing Scientifically – Review Article Writing.* Presented as part of Curricular Track 2 at the American College of Clinical Pharmacy 2008 Spring Practice and Research Forum, Phoenix, AZ, April 2008.
64. *Meeting the Challenge of Thromboembolic Disease: A Case-Based Approach.* Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2007.
65. *Duration of Anti-Platelet Therapy Should Be Continued Indefinitely for the Prevention of In-Stent Thrombosis: Statement For.* Presented as part of the Cardiology PRN Focus Session at the American College of Clinical Pharmacy Annual Meeting, Denver, CO, October 2007.
66. *Antithrombotic Therapy Evolving Evidence: Clinical Considerations in the Use of Antithrombotic Therapy for Acute Coronary Syndrome.* Chaired and presented as part of a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2006.
67. *Pharmacological Considerations in Acute Coronary Syndrome: An Expert Debate – Role of Glycoprotein IIb/IIIa Inhibitors with Heparin/Low-Molecular Weight Heparin Versus Bivalirudin: The Evidence Favors GP IIb/IIIa Inhibitors.* Presented as part of a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Anaheim, CA, December 2006.
68. *Is There Evidence for Using Low Molecular Weight Heparins as Bridge Therapy for Patients with Atrial Fibrillation?* Presented as part of the Internal Medicine PRN Focus Session at the American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 2006.
69. *Ischemia: New Medical Therapies, New Understanding – Stable Angina: Current State of Disease Management.* Chaired and presented as part of a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 2006.
70. *Acute Decompensated Heart Failure: Controversies, Guidelines, and Future Directions - The Future of Acute Decompensated Heart Failure: What's Next?* Presented as part of a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 2006.
71. *Antithrombotic Therapy Evolving Evidence: Clinical Considerations in the Use of Antithrombotic Therapy for Acute Coronary Syndrome.* Chaired and presented as part of a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 2006.
72. *Medical Therapy in Acute Coronary Syndrome: Focus on Antithrombotic Therapy – The role of Antithrombotic Therapy in ACS.* Presented as part of a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2005.
73. *Update in Cardiovascular Therapeutics - Controversies in Percutaneous Coronary Intervention.* Presented as part of the Cardiology Practice and Research Network pre-meeting symposium at the American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 2005.
74. *Medical Therapy in Acute Coronary Syndrome: Focus on Antithrombotic Therapy – The role of Antithrombotic Therapy in ACS.* Presented as part of a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 2005.
75. *Consensus on Contemporary UFH Issues: Highlights from the 2004 White Paper - Economic Considerations.* Presented as part of a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Orlando, FL, December 2004.

76. *Pravastatin or Atorvastatin Evaluation and Infection Therapy: PROVE IT - TIMI 22*. Presented as the significant paper in cardiology at the American College of Clinical Pharmacy Annual Meeting, Dallas, TX, October 2004.
77. *Advances in the Management of Venous Thromboembolism (VTE) - VTE Prophylaxis at the Crossroads: Charting the Impact of Newer Agents*. Presented as an industry classroom at the 2004 Updates in Therapeutics: Pharmacotherapy Preparatory Course of the American College of Clinical Pharmacy, Austin, TX, June 2004.
78. *Therapeutic Debates in Hematology: Enoxaparin is the Superior Low Molecular Weight Heparin – the Pro Argument*. Presented as one of four debates in hematology at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2003.
79. *Contemporary Clinical Practice: State of the Art VTE Management – Emerging Data in VTE Prophylaxis*. Presented as part of a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, Atlanta, GA, November 2003.
80. *Improving Outcomes in Patients at Risk of VTE – Venous Thromboembolism: Who is at Risk?* Presented as part of a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta, GA, December 2002.
81. *Evolution in the Management of Thrombotic Disorders: The Role of Factor Xa Inhibition in the Continuum of Care – Novel Concepts: Emerging Data and the Role of Extended Prophylaxis Following Hip-Fracture Surgery*. Presented as part of a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta, GA, December 2002.
82. *LMWH Horizons: New Uses, New Evidence, New Agents*. Moderator of program presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta, GA, December 2002.
83. *Secondary Prevention of Stroke: A Closer Look at the Evidence - Aspirin as First-Line Therapy*. Presented as part of the evidence-based medicine curricular track at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October 2002.
84. *Anticoagulation in Cardiology: Past, Present, and Future – The Present: What do the Data Tell Us?* Presented as part of a satellite symposium at the American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October 2002.
85. *Signs and Symptoms of Acute Coronary Syndromes*. Presented as part of a Learning Community on Treating Cardiovascular Disease in the Acute Care Setting at the American Society of Health-Systems Pharmacists Annual Meeting, Baltimore, MD, June 2002.
86. *Pharmacotherapy with Angioplasty*. Presented as part of a Learning Community on Treating Cardiovascular Disease in the Acute Care Setting at the American Society of Health-Systems Pharmacists Annual Meeting, Baltimore, MD, June 2002.
87. *Secondary Prevention of Acute Myocardial Infarction*. Presented as part of a Learning Community on Treating Cardiovascular Disease in the Acute Care Setting at the American Society of Health-Systems Pharmacists Annual Meeting, Baltimore, MD, June 2002.
88. *Are IIb's Me Too's: Differentiating Evidence and Value*. Moderator of program presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2001.
89. *Thrombolytics and All That Jazz: A Big Decision Made Easy - Lytics ± GP IIb/IIIa Inhibitors in STEMI: Which One(s), Why, and When*. Presented as a satellite symposium at the American

Society of Health-Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 2001.

90. *Acute Coronary Syndromes: Differentiating Between GP IIb/IIIa blockers.* Moderator of program presented in conjunction with the American Society of Health-Systems Pharmacist Midyear Meeting, Las Vegas, NV, December 2000.
91. *Oral Fibans "Meet the Experts".* Presented as a satellite symposium at the American Society of Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 1998.

State Annual Meetings

1. *2019 Cardiology Update – Reversal of Oral Anticoagulation Therapy.* Presented the Kansas City Cardiology Annual Meeting, Kansas City, KS, April 2019.
2. *Meeting Today's Healthcare Delivery Challenges – Best Practices for Reducing Hospital Readmissions.* Presented at the Pharmacy Society of Wisconsin Conference on Advanced Medication Management for the Elderly, Waukesha, WI, June 2018.
3. *Arterial Disease and Antithrombotic Therapy.* Presented at the Amcare Pharmacy Forum of North Carolina, Charlotte, NC, January 2018.
4. *Reducing Hospital Readmissions in Heart Failure: Pharmacy's Pivotal Role.* Presented at the Alabama Society of Health-System Pharmacists Annual Meeting, Destin, FL, June 2017.
5. *Reducing Hospital Readmissions in Heart Failure: Pharmacy's Pivotal Role.* Presented at the Colorado Society of Health-System Pharmacists Annual Meeting, Aurora, CO, June 2017.
6. *Reducing Hospital Readmissions in Heart Failure: Pharmacy's Pivotal Role.* Presented at the Louisiana Society of Health-System Pharmacists Annual Meeting, New Orleans, LA, May 2017.
7. *How Study Designs Prohibit Us from Comparing DOACs.* Presented at the Heart Rhythm Society 10th Annual Western Atrial Fibrillation Symposium, Park City, UT, February 2017.
8. *Managing the Patient with Heart Failure: The Role of the Case Manager as a Team Player.* Presented at the Phoenix/Scottsdale Chapter of the Case Managers Society of American Annual Meeting, Scottsdale, AZ, February 2017.
9. *Heart, Lung, Vascular Update for Primary Care Providers: Frontline Strategies – What is the Role of Bridging and How Does it Fit in Using Novel Anticoagulants?* Presented at The University of Tennessee Graduate School of Medicine and Department of Internal Medicine Annual Meeting, Knoxville, TN, October 2016.
10. *Heart, Lung, Vascular Update for Primary Care Providers: Frontline Strategies – Novel Anticoagulants.* Presented at The University of Tennessee Graduate School of Medicine and Department of Internal Medicine Annual Meeting, Knoxville, TN, October 2015.
11. *Evolving Strategies for Stroke Prevention in Patients with Atrial Fibrillation.* Presented at the New York State Society of Health-Systems Pharmacists Annual Meeting, Saratoga, NY, May 2014.
12. *Essential Guidelines for Hospital Pharmacists in Acute Coronary Syndrome.* Presented at the Connecticut Society of Health-Systems Pharmacists Annual Meeting, Cromwell, CT, November 2013.

13. *Heart, Lung, Vascular Update for Primary Care Providers: Frontline Strategies – Novel Anticoagulants.* Presented at The University of Tennessee Graduate School of Medicine and Department of Internal Medicine Annual Meeting, Knoxville, TN, September 2013.
14. *Essential Guidelines for Hospital Pharmacists in Acute Coronary Syndrome.* Presented at the Illinois Society of Health-Systems Pharmacists Annual Meeting, Oakbrook, IL, September 2013.
15. *New Oral Anticoagulants: Promises and Pitfalls.* Presented at the Arizona Pharmacy Association 8th Annual Meeting, Litchfield Park, AZ, June 2012.
16. *Heart, Lung, Vascular Update for Primary Care Providers: Frontline Strategies – Anticoagulation Strategies in Atrial Fibrillation.* Presented at The University of Tennessee Graduate School of Medicine and Department of Internal Medicine Annual Meeting, Knoxville, TN, September 2011.
17. *Management of Chronic Heart Failure.* Presented at the Nebraska Pharmacists Association Annual Meeting, Omaha, NE, June 2009.
18. *Applying ACC/AHA Guidelines to Anticoagulant Therapy in the Management of Acute Coronary Syndrome.* Presented at the Missouri and Kansas Societies of Health-Systems Pharmacists Annual Meeting, Overland Park, KS, April 2008.
19. *Evidence-based Strategies for Improving Patient Outcomes: Optimizing Antithrombotic Management of Acute Coronary Syndrome.* Presented at the Maine Society of Health-Systems Pharmacy Annual Meeting, Hallowell, ME, October 2007.
20. *Evidence-based Strategies for Improving Patient Outcomes: Focus on Antithrombotic Therapy in the Management of Acute Coronary Syndrome.* Presented at the Colorado Pharmacists Society Annual Meeting, Denver, CO, October 2007.
21. *Management of Peripheral Arterial Disease.* Presented at the Kansas Pharmacists Association Annual Meeting, Hays, KS, August 2007.
22. *Evidence-Based Strategies for Improving Patient Outcomes: Antithrombotic Therapy in the Prevention and Management of Venous Thromboembolism.* Presented at the Florida Society of Health-Systems Pharmacy Annual Meeting, Orlando, FL, August 2007.
23. *Evidence-Based Strategies for Improving Patient Outcomes: Antithrombotic Therapy in the Prevention and Management of Venous Thromboembolism.* Presented at the Georgia Society of Health-Systems Pharmacy Annual Meeting, Amelia Island, FL, July 2007.
24. *Evidence-based Strategies for Improving Patient Outcomes: Optimizing Antithrombotic Management of Acute Coronary Syndrome.* Presented at the Washington State Pharmacy Association Annual Meeting, Coeur D'Alene, ID, June 2007.
25. *Evidence-based Strategies for Improving Patient Outcomes in the Prevention and Management of Venous Thromboembolism: Focus on Antithrombotic Therapy.* Presented at the Alabama Society of Health-Systems Pharmacists Annual Meeting, Point Clear, AL, June 2007.
26. *Evidence-based Strategies for Improving Patient Outcomes: Focus on Antithrombotic Therapy in the Management of Acute Coronary Syndrome.* Presented at the Wisconsin Society of Health-Systems Pharmacists Annual Meeting, Madison, WI, April 2007.
27. *Evidence-Based Strategies for Improving Patient Outcomes: Antithrombotic Therapy in the Prevention and Management of Venous Thromboembolism.* Presented at the Virginia Society of Health-Systems Pharmacists Annual Meeting, Wintergreen, VA, April 2007.

28. *Pharmacology of Old and New Antithrombotic Agents.* Presented at the Nebraska Nurse Practitioners 16th Annual Conference, Kearney, NE, January 2007.
29. *Prevention and Treatment of Venous Thromboembolic Disease.* Presented at the Nebraska Nurse Practitioners 16th Annual Conference, Kearney, NE, January 2007.
30. *Prevention and Treatment of VTE in Trauma Patients.* Presented at Trauma Education Day 2006, Peoria, IL, September 2006.
31. *New Evidence for the Clinical and Economic Management of Acute Decompensated Heart Failure - Evidence-Based Pharmacotherapy for the Management of Acute Decompensated Heart Failure.* Presented as a symposium at the California State Society of Health-Systems Pharmacists Annual Meeting, Anaheim, CA, October 2005.
32. *Update on LMWHs in ACS: Challenging the Heparin Paradigm.* Presented as a symposium at the California State Society of Health-Systems Pharmacists Annual Meeting, Anaheim, CA, October 2005.
33. *New Evidence for the Clinical and Economic Management of Acute Decompensated Heart Failure - Evidence-Based Pharmacotherapy for the Management of Acute Decompensated Heart Failure.* Presented as a symposium at the Illinois State Society of Health-Systems Pharmacists Annual Meeting, Oakbrook, IL, September 2005.
34. *New Evidence for the Clinical and Economic Management of Acute Decompensated Heart Failure - Evidence-Based Pharmacotherapy for the Management of Acute Decompensated Heart Failure.* Presented as a symposium at the Florida State Society of Health-Systems Pharmacists Annual Meeting, Kissimmee, FL, August 2005.
35. *New Evidence for the Clinical and Economic Management of Acute Decompensated Heart Failure - Evidence-Based Pharmacotherapy for the Management of Acute Decompensated Heart Failure.* Presented as a symposium at the Georgia State Society of Health-Systems Pharmacists Annual Meeting, Amelia Island, FL, July 2005.
36. *Venous Thromboembolism Prevention in High-Risk Patients.* Presented at the 23rd Annual Symposium of the American Association of Critical Care Nurses Greater St. Louis Chapter, St. Louis, MO, March 2005.
37. *Improvement in the Quantity and Quality of VTE Prophylaxis for Medically Ill Patients: Impact of a Clinical Pharmacy Education Program.* Presented at the 19th Annual Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT), Orlando, FL, December 2004.
38. *Anti-thrombotic Controversies in the Critically Ill Patient.* Presented at the 1st Annual New England Critical Care Pharmacy Symposium, Boston, MA, April 2004.
39. *Venous Thromboembolism Prevention and Treatment.* Presented at the Iowa Pharmacy Association's 5th Annual Senior Care Conference, Des Moines, IA, October 2003.
40. *An Update on Acute Coronary Syndromes.* Presented at the Fourth Annual Ozark Area Pharmacy Association Day of Education, Springfield, MO, October 2003.
41. *Drug-Eluting Stents: A Mechanical and Pharmacological Approach to Coronary Artery Disease.* Presented at the Kentucky Society of Health-Systems Pharmacists 2003 Fall Meeting, Lexington, KY, September 2003.
42. *ACC/AHA Guidelines for the Management of UA and NSTEMI.* Presented at the Missouri and Illinois Societies of Health-Systems Pharmacists Annual Meeting, St. Louis, MO, April, 2003.

43. *ACC/AHA Guidelines for the Management of UA and NSTEMI.* Presented at the Wisconsin Society of Health-Systems Pharmacists Annual Meeting, Madison, WI, April 2003.
44. *Evidence and Economics of GP IIb/IIIa Inhibitors.* Presented at the Eastern Florida Society of Health-System Pharmacists Annual Meeting, Tampa, FL, October 2002.
45. *Integrating New Fibrinolytic Findings into AMI Reperfusion and Combination Therapy: 2002.* Presented at the Louisiana Society of Health-System Pharmacists Annual Meeting, Shreveport, LA, October 2002.
46. *Role of BNP in Patients with Heart Failure.* Presented at the Gateway College of Clinical Pharmacy and Mid-America College of Clinical Pharmacy Joint Annual Meeting, Branson, MO, August 2002.
47. *New Horizons in AMI Treatment.* Presented at the Gateway College of Clinical Pharmacy and Mid-America College of Clinical Pharmacy Joint Annual Meeting, Branson, MO, August 2002.
48. *Evidence and Economics of GP IIb/IIIa Inhibitors.* Presented at the Blue Ridge Interventional Cardiology Conference 2002, Hot Springs, VA, May 2002.
49. *Update on the Treatment of Acute Coronary Syndromes: Role of GP IIb/IIIa Inhibitors. Which Ones and When?* Presented at the Wisconsin Society of Health-Systems Pharmacists Annual Meeting, Madison, WI, April 2002.
50. *Update on the Treatment of Acute Coronary Syndromes: Role of GP IIb/IIIa Inhibitors. Which Ones and When?* Presented at the West Virginia Society of Health-Systems Pharmacists Annual Meeting, Charleston, WV, April 2002.
51. *Integrating New Fibrinolytic Findings into AMI Reperfusion and Combination Therapy.* Presented at the Missouri Society of Health-Systems Pharmacists Annual Meeting, Columbia, MO, October 2001.
52. *Economic Consideration of GP IIb/IIIa Inhibitor Therapy.* Presented at the Kentucky Society of Health-Systems Pharmacists Spring Forum, Louisville, KY, May 2001.
53. *Economic and Reimbursement Issues of GP IIb/IIIa Inhibitor Therapy.* Presented at the Florida Society of Health-Systems Pharmacists Spring Forum. Ft. Lauderdale, FL, March 2001.
54. *Economic and Reimbursement Issues of GP IIb/IIIa Inhibitor Therapy.* Presented at the Georgia Society of Health-Systems Pharmacists Annual Meeting, Atlanta, GA, January 2001.
55. *Economic Considerations of GP IIb/IIIa Inhibitor Therapy.* Presented at the South Dakota Society of Health Systems Pharmacists Annual Meeting, Sioux Falls, SD, September 2000.
56. *Acute Coronary Syndromes: Differentiating Between GP IIb/IIIa blockers.* Presented at the New York State Council of Health System Pharmacists Annual Symposium on Acute Coronary Syndromes, Atlantic City, NJ, September 2000.
57. *Beyond BADD Heart Failure.* Presented at the Gateway College of Clinical Pharmacy and Mid-America College of Clinical Pharmacy Joint Annual Meeting, Lake of the Ozarks, MO, August 2000.
58. *Defusing Thrombotic Risk Using an Evidence-Based LMWH Formulary.* Presented to Wisconsin Society of Health Systems Pharmacists Annual Meeting, Stevens Point, WI, August 2000.

Local Organization Meetings

1. *Antithrombotics: Silent Killer of all Killers*. Presented at the University of Nebraska Medical Center and Nebraska Medicine 2015 Trauma Symposium, Omaha, NE, October 2015.
2. *Antiplatelet Therapy in the Management of Acute Coronary Syndrome*. Presented to the Blackhawk – Bremer Pharmacy Association, Wahoo, IA, March 2015.
3. *Discovering What's New in the Management of ACS*. Presented to the Linn County Pharmacists Association, Cedar Rapids, IA, September 2014.
4. *Evolving Strategies for Stroke Prevention in Patients with Atrial Fibrillation*. Presented to the Tennessee Society of Health-Systems Pharmacists, Franklin, TN, August 2014.
5. *New Oral Anticoagulants in the Prevention and Treatment of Thrombosis*. Presented to the Southwest Iowa Pharmacists Association, Omaha, NE, June 2014
6. *Essential Guidelines for Hospital Pharmacists in Acute Coronary Syndrome*. Presented to the Long Island Affiliate Chapter of the New York State Council of Health-Systems Pharmacists, Long Island, NY, September 2013.
7. *Overview of Antiplatelet Therapy – Post Angioplasty and Stenting*. Presented at the Sanford Health 2013 Cardiovascular Symposium, Sioux Falls, SD, September 2013.
8. *Essential Guidelines for Hospital Pharmacists in Acute Coronary Syndrome*. Presented to the Diablo Affiliate Chapter of the California Society of Health-Systems Pharmacists, Walnut Creek, CA, July 2013.
9. *Update on Clinical Applications of New Oral Anticoagulants*. Presented with Brian Trevarrow, Pharm.D. to the Mid-West College of Clinical Pharmacy, Omaha, NE, April 2013
10. *Essential Guidelines for Hospital Pharmacists in Acute Coronary Syndrome*. Presented to the Southern Affiliate Chapter of the New Jersey Society of Health-Systems Pharmacists, Cherry Hill, NJ, April 2013.
11. *VTE Prevention in High-Risk Medical Patients*. Presented to the Western Oklahoma Society of Health Systems Pharmacists, Oklahoma City, OK, March 2009.
12. *VTE Prevention in High-Risk Medical Patients*. Presented to the Eastern Oklahoma Society of Health Systems Pharmacists, Tulsa, OK, January 2009.
13. *A Case-Based Approach to Optimizing Anticoagulant Therapy in Acute Coronary Syndrome*. Presented to the Southeast Florida Society of Health-Systems Pharmacists, Ft. Lauderdale, FL, October 2008.
14. *The Evolution of Anticoagulant Therapy in ACS*. Presented to the Birmingham-Tuscaloosa Region of the Alabama Society of Health-Systems Pharmacists, Birmingham, AL, July 2008.
15. *Improving Outcomes of Anticoagulant Therapy in Patients with Non-ST-Elevation Acute Coronary Syndrome: 2008 Update*. Presented to the Gulf Coast Society of Health-Systems Pharmacists, Houston, TX, May 2008.
16. *Evidence-based Strategies for Improving Patient Outcomes: Optimizing Antithrombotic Management of Acute Coronary Syndrome*. Presented to the Oregon Society of Health-Systems Pharmacists, Portland, OR, January 2008.

17. *Evidence-based Strategies for Improving Patient Outcomes: Focus on Antithrombotic Therapy in the Management of Acute Coronary Syndrome.* Presented to the Boston Council of Teaching Hospitals, Boston, MA, October 2007.
18. *Evidence-Based Strategies for Improving Patient Outcomes: Antithrombotic Therapy in the Prevention and Management of Venous Thromboembolism.* Presented to the Boston Council of Teaching Hospitals, Boston, MA, October 2007.
19. *Evolving Anticoagulation Concepts in Acute Coronary Syndrome.* Presented to the Birmingham-Tuscaloosa Region of the Alabama Society of Health-Systems Pharmacists, Birmingham, AL, August 2007.
20. *Evolving Anticoagulation Concepts in Acute Coronary Syndrome.* Presented to the Central Savannah River District of the Georgia Society of Health-Systems Pharmacists, Augusta, GA, August 2007.
21. *VTE Prophylaxis in High-Risk Medical Patients.* Presented to the Mid-West College of Clinical Pharmacists, Omaha, NE, March 2007.
22. *Evolving Antithrombotic Therapy in ACS.* Presented to the Mid-Missouri Society of Health-Systems Pharmacists, Columbia, MO, October 2006.
23. *Acute Heart Failure Guidelines: What Do They Say and Why Do They Say It?* Presented to the Mid-West College of Clinical Pharmacists, Omaha, NE, September 2006.
24. *Optimizing the Prophylaxis and Treatment of VTE: Enhancing Awareness, Management, and Quality.* Presented to the Mid-Texas Society of Health-Systems Pharmacists, San Angelo, TX, August 2006.
25. *Prevention and Treatment of VTE.* Presented to the North Central Society of Health-Systems Pharmacists, Cedar Rapids, IA, January 2006.
26. *Therapeutic Advances in Acute Decompensated Heart Failure.* Presented to the Palm Beach Section of the Florida Society of Health-Systems Pharmacists, West Palm Beach, FL, August 2005.
27. *Therapeutic Advances in Acute Decompensated Heart Failure.* Presented to the Inland Society of Health-Systems Pharmacists, Ontario, CA, May 2005.
28. *VTE Prophylaxis in High-Risk Medical Patients.* Presented to the Central Iowa Pharmacists Association, Des Moines, IA, April 2005.
29. *Challenging the Heparin Paradigm in Cardiology: The Evidence-Based Role of LMWHs.* Presented to Kansas City Metro Society of Health-Systems Pharmacists, Kansas City, MO, October 2004
30. *Challenging the Heparin Paradigm in Cardiology: The Evidence-Based Role of LMWHs.* Presented to the River City Roadrunner chapter of the Emergency Room Nursing Association, Evansville, IN, September 2004.
31. *VTE Prophylaxis in Medically Ill Patients.* Presented to the IPC Hospitalists' Company, St. Louis, MO, August 2004.
32. *Anticoagulation Issues in the Emergency Room.* Presented to the Republic Emergency Services Group of emergency room physicians, Dallas, TX, August 2004.

33. *Opening the Therapeutic Window in Acute Decompensated Heart Failure: Closing in on the Value of Nesiritide.* Presented to Eastern Oklahoma Society of Health Systems Pharmacists, Tulsa, OK, July 2004.
34. *Prevention of Venous Thromboembolism.* Presented to Northern Louisiana Society of Health-Systems Pharmacists, Shreveport, LA, February 2004.
35. *Prevention and Treatment of Venous Thromboembolism.* Presented to Central Illinois Pharmacists Association, Peoria, Illinois, January 2004.
36. *Optimizing Injectable Anticoagulant Formulary: Considerations with LMWH Interchange and Novel Agents.* Presented to Metropolitan Oncology Pharmacy Association, Dallas, TX, October 2003.
37. *Optimizing Injectable Anticoagulant Formulary: Considerations with LMWH Interchange and Novel Agents.* Presented to Ozark Area Pharmacy Association, Joplin, MO, June 2003.
38. *Bridging Therapy: Who, When, and How?* Presented to the Northwest Anticoagulation Consortium, Renton, WA, May 2003.
39. *Challenging VTE Standards: Heparin, LMWHs, and Evolving Agents.* Presented to the Missouri Pharmaceutical Association, Columbia, MO, April 2003.
40. *Challenging VTE Standards: Heparin, LMWHs, and Evolving Agents.* Presented to the Big Country Pharmaceutical Association, Abilene, TX, March 2003.
41. *LMWH Horizons: New Uses, New Evidence, New Agents.* Presented to the Dubuque Area Pharmacy Association, Dubuque, IA, January 2003.
42. *LMWH Horizons: New Uses, New Evidence, New Agents.* Presented to Southern Indiana Society of Health-Systems Pharmacists, Evansville, IN, November 2002.
43. *LMWH Horizons: New Uses, New Evidence, New Agents.* Presented to Eastern Kentucky Pharmaceutical Association, Paducah, KY, August 2002.
44. *Integrating New Fibrinolytic Findings into AMI Reperfusion and Combination Therapy: 2002.* Presented to Ozark Area Pharmacy Association, Joplin, MO, April 2002.
45. *Fibrinolysis in Catheter and Peripheral Arterial Thrombosis.* Presented to Ozark Area Pharmacy Association, Joplin, MO, April 2002.
46. *Integrating New Fibrinolytic Findings into AMI Reperfusion and Combination Therapy: 2002.* Presented to Ozark Area Pharmacy Association, Springfield, MO, April 2002.
47. *Fibrinolysis in Catheter and Peripheral Arterial Thrombosis.* Presented to Ozark Area Pharmacy Association, Springfield, MO, April 2002.
48. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to the Brazos Valley Pharmacy Association, College Station, TX, November 2001.
49. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to Lake Havasu Pharmacy Association, Lake Havasu, AZ, October 2001
50. *Are Iib's Me Too's? Differentiating Evidence and Value.* Presented to South Dakota Society of Health-Systems Pharmacists, Sioux Falls, SD, September 2001.
51. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to the Western Arkansas Pharmaceutical Association, Fort Smith, AK, September 2001.

52. *Are IIb's Me Too's? Differentiating Evidence and Value.* Presented to South Carolina Society of Health-Systems Pharmacists, Charleston, SC, August 2001
53. *Integrating New Fibrinolytic Findings into AMI Reperfusion and Combination Therapy.* Presented to Southern Colorado Society of Health-Systems Pharmacist, Colorado Springs, CO, August 2001.
54. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to the Northern Texas Pharmaceutical Association, Wichita Falls, TX, August 2001.
55. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to the Western Florida Society of Health-Systems Pharmacists meeting, Tampa, FL, July 2001.
56. *Interrupting the Sepsis Cascade: Innovations in Biotechnology.* Presented to the Mississippi Society of Health-Systems Pharmacists, Jackson, MS, June 2001.
57. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to the Eastern Society of Health-Systems Pharmacists, Knoxville, TN, June 2001.
58. *Fibrinolysis: Peripheral Arterial Occlusion and Central Venous Catheter Clearance. Clinical and Economic Alternatives.* Presented to the Eastern Oklahoma Society of Health-Systems Pharmacists, Tulsa, OK, April 2001.
59. *Are IIb's Me Too's? Differentiating Evidence and Value.* Presented to the Southern Oregon Society of Health-Systems Pharmacists, Medford, OR, April 2001.
60. *Evidence and Economics Surrounding the Use of GP IIb/IIIa Inhibitor Therapy.* Presented at the Cleveland Society of Health-System Pharmacist Spring Meeting. Cleveland, OH, March 2001.
61. *Consensus of LMWH Differentiation: Issues and Evolving Evidence.* Presented to the Far Southern Illinois Society of Health-Systems Pharmacists, Heron, IL, March 2001.
62. *An Evidence-Based Approach to Using Glycoprotein IIb/IIIa Antagonist in the New Millennium.* Presented to the Southeast Florida Society of Health-Systems Pharmacists. Ft. Lauderdale, FL, February 2001.
63. *Arterial Fibrinolysis: Targeting MI and Stroke.* Presented to Metro East Illinois Society of Health-Systems Pharmacists, Belleville, IL, January 2001.
64. *Economic Considerations of GP IIb/IIIa Inhibitor Therapy.* Presented to Northeast Society of Health-Systems Pharmacists, Jefferson City, TN, November 2000.
65. *Acute Coronary Syndromes: Differentiating Between GP IIb/IIIa blockers.* Presented to the Southwest Florida Society of Health-Systems Pharmacists, Tampa, FL, September 2000.
66. *Arterial Fibrinolysis: Targeting MI and Stroke.* Presented to Northwest Arkansas Pharmaceutical Association, Rogers, AK, August 2000.
67. *Acute Coronary Syndromes: Differentiating Between GP IIb/IIIa blockers.* Presented to Colorado Society of Health Systems Pharmacists, Denver, CO, August 2000.
68. *Arterial Fibrinolysis: Targeting MI and Stroke.* Presented to Eastern Oklahoma Society of Health-System Pharmacists, Tulsa, OK, July 2000.
69. *Arterial Fibrinolysis: Targeting MI and Stroke.* Presented to Western Oklahoma Society of Health-System Pharmacists, Oklahoma City, OK, July 2000

70. *Defusing Thrombotic Risk Using an Evidence-Based LMWH Formulary.* Presented to Cleveland County Pharmaceutical Association, Norman, OK, July 2000.
71. *Arterial Fibrinolysis: Targeting MI and Stroke.* Presented to Northern Louisiana Society of Health-System Pharmacists, Shreveport, LA, June 2000.
72. *Defusing Thrombotic Risk Using an Evidence-Based LMWH Formulary.* Presented to New Mexico Pharmaceutical Association, Albuquerque, NM, May 2000.
73. *Arterial Fibrinolysis: Targeting MI and Stroke.* Presented to Kansas Society of Health-System Pharmacists, Topeka, KS, May 2000.
74. *Defusing Thrombotic Risk Using an Evidence-Based LMWH Formulary.* Presented to Northern Louisiana Society of Health-System Pharmacists, Shreveport, LA, April 2000.
75. *Defusing Thrombotic Risk Using an Evidence-Based LMWH Formulary.* Presented to West Central Illinois Society of Health-System Pharmacists, Peoria, IL, April 2000.
76. *Acute Coronary Syndromes: Preeminence of Antiplatelet Therapy.* Presented to Northern Louisiana Society of Health-System Pharmacists, Shreveport, LA, January 2000.
77. *Brain Attack: Pursuing Enhanced Outcomes.* Presented to Ozark Area Pharmacy Association, Springfield, MO, December 1999.
78. *Myocardial Infarction: An Evidence-Based Approach to Pharmacotherapy.* Presented to Ozark Area Pharmacy Association, Joplin, MO, December 1999.
79. *Acute Coronary Syndromes: Preeminence of Antiplatelet Therapy.* Presented to Oklahoma Society of Health-System Pharmacists, Tulsa, OK, November 1999.
80. *Myocardial Infarction: An Evidence-Based Approach to Pharmacotherapy.* Presented to Ozark Area Pharmacy Association, Springfield, MO, September 1999.

INTERNET-BASED NATIONAL EDUCATION

1. *Pharmacist-Led Transitions of Care: Improving Outcomes for Extended Thromboprophylaxis in High Risk Medically Ill Patients.* Supported by Power-Pak. Presented on May 12, 2021 and enduring for one year and a total of 1338 participants.
2. *2019 Pharmacotherapy Updates Plus Webinar – AUGUSTUS Trial and Triple Therapy.* Supported by the American College of Clinical Pharmacy. Presented to 25 sites on November 7, 2019.
3. *Novel DOAC Reversal Strategies: Update on Best Practices.* Supported by the North American Center for Continuing Medical Education. Presented to 371 sites on April 18th, 24th, 25th, 26th, and 29th 2019.
4. *Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.* Supported by the Anticoagulation FORUM. Presented to 447 sites and 550 participants on March 28, 2018.
5. *Clinical Case Studies in Venous Thromboembolism: Addressing Clinical Issues in Special Patient Populations.* Supported by ASHP Advantage. Presented to 1087 sites and 1340 participants on May 10, 2017.
6. *Managing Heparin Anticoagulants in VTE Treatment.* Supported by the Anticoagulation FORUM. Presented to 323 sites on August 17, 2016.

7. *Practical Approaches to Managing Antiplatelet Therapy in Acute Coronary Syndrome*. Supported by ASHP Advantage. Presented to 1754 sites and 1947 participants on September 17th and October 7, 2014.
8. *Stroke Prevention: The Personalized Anticoagulation Regimen*. Supported by APhA. Presented to 209 sites on September 23rd and October 2nd 2014.
9. *Management of Bleeding and Reversal of the New Anticoagulant Agents*. Supported by MedAssets. Presented to 163 sites and 313 participants on May 30, 2012.
10. *Ask the Expert: Practice Pearls for Optimizing Oral Antiplatelet Therapy in Acute Coronary Syndrome*. Supported by ASHP Advantage. Presented to 670 sites and 883 participants on March 2, 2011.
11. *Ensuring Safe and Effective ACS Medication Selection, Administration, and Adherence in the Community Setting*. Supported by the North American Center for Continuing Medical Education. Presented to 448 sites on December 1st, 2nd, 3rd, 7th, 8th, and 13th 2010.
12. *Highlights from the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH): Noteworthy News for Pharmacists Managing Antithrombotic Therapy*. Supported by ASHP Advantage. Presented to 1200 sites on August 6th, August 19th, September 1st, and September 15th 2009.
13. *Cutting Edge Research Presented at the 2008 American Heart Association Meeting*. Supported by ASHP Advantage. Presented to 651 sites on December 2 and 17, 2008.
14. *VTE and the Hospital Pharmacist Implementing Optimal Management Protocols*. Supported by the North American Center for Continuing Medical Education. Presented on September 15, September 16, September 17, and September 18, 2008. Enduring program for 1 year following live presentations.
15. *New American College of Chest Physicians Antithrombotic Therapy Guidelines: Implications for Acute Coronary Syndrome Management*. Supported by ASHP Advantage. Presented to 607 sites on August 21, September 17, and September 25, 2008.
16. *Applying ACC/AHA Guidelines to Anticoagulant Therapy in the Management of Acute Coronary Syndrome*. Supported by ASHP Advantage. Enduring program from June 1, 2008 to December 31, 2008.
17. *Antiplatelet Therapy in Percutaneous Coronary Intervention: An Educational Initiative for Clinical and Managed Care Pharmacists*. Supported by the North American Center for Continuing Medical Education. Presented on February 7, February 8, February 13, and February 15, 2008.
18. *Evidence-Based Strategies for Improving Patient Outcomes in the Prevention and Management of Venous Thromboembolism: Focus on Antithrombotic Therapy*. Supported by ASHP Advantage. Presented to 76 sites on October 11, 2007.
19. *Evidence-Based Strategies for Improving Patient Outcomes: Optimizing Antithrombotic Management of Acute Coronary Syndrome*. Supported by ASHP Advantage. Presented to 91 sites on October 9, 2007.
20. *Management of ST-Segment Elevation Myocardial Infarction: Weighing the Developments of 2007 for Improved Outcomes*. Supported by the North American Center for Continuing Medical Education. Presented on May 17, May 18, October 10, and October 12, 2007. Enduring program for 1 year following live presentations.

21. *VTE Prevention in the Hospital: The Medically Ill Patient.* Supported by the North American Center for Continuing Medical Education. Presented on July 11, July 12, July 13, and July 15, 2005. Enduring program for 1 year following live presentations.
22. *Medication Safety in Venous Thromboembolism Prevention: The Move to Second-Generation Heparin.* Supported by the North American Center for Continuing Medical Education. Enduring program from May 1, 2004 to May 1, 2005.
23. *The Role of Managed Care in Venous Thromboembolism Prevention.* Supported by the North American Center for Continuing Medical Education. Enduring program from December 31, 2003 to December 31, 2004.

INSTITUTIONAL EDUCATION

1. *DAPT Challenges: Treatment Duration and Triple vs. Double Therapy.* Presented as grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, December 2021.
2. *Are One of These Not Like the Others? DOACs for NVAF.* Presented to cardiology faculty and fellows, medicine residents, and physician assistant, medicine, and pharmacy students at UNMC/Nebraska Medicine, Omaha, NE, November 2021.
3. *DAPT Challenges: Treatment Duration and Triple vs. Double Therapy.* Presented as grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, December 2020.
4. *Are One of These Not Like the Others? DOACs for NVAF.* Presented to cardiology faculty and fellows, medicine residents, and physician assistant, medicine, and pharmacy students at UNMC/Nebraska Medicine, Omaha, NE, October 2020.
5. *Reversal of Oral Anticoagulants.* Presented to cardiology faculty and fellows, medicine residents, and physician assistant, medicine, and pharmacy students at UNMC/Nebraska Medicine, Omaha, NE, August 2020.
6. *Are One of These Not Like the Others? DOACs for NVAF.* Presented to cardiology faculty and fellows, medicine residents, and physician assistant, medicine, and pharmacy students at UNMC/Nebraska Medicine, Omaha, NE, August 2020.
7. *Extended Prophylaxis in Medically Ill Patients.* Presented as a grand rounds to the UNMC/Nebraska Medicine Internal Medicine Department, Omaha, NE, February 2019.
8. *Extended Prophylaxis in Medically Ill Patients.* Presented as a grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, November 2018.
9. *Clinical Controversies and Questions Surrounding the use of Direct Oral Anticoagulants.* Presented to medicine and pharmacy faculty, residents, and students at UNMC/Nebraska Medicine, Omaha, NE, August 2018.
10. *Arterial Disease and Oral Anticoagulation.* Presented as a grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, August 2018.
11. *Clinical Controversies and Questions Surrounding the use of Direct Oral Anticoagulants.* Presented to medicine and pharmacy faculty, residents, and students at UNMC/Nebraska Medicine, Omaha, NE, December 2017.

12. *Pharmacology and Clinical Evidence of Oral Antiplatelet Agents.* Presented to medicine and pharmacy faculty, residents, and students at UNMC/Nebraska Medicine, Omaha, NE, December 2017.
13. *Arterial Disease and Oral Anticoagulation.* Presented as a grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, December 2017.
14. *Use of DOACs in the Management of Atrial Fibrillation.* Presented to medicine and pharmacy faculty, residents, and students at UNMC/Nebraska Medicine, Omaha, NE, August 2017.
15. *Clinical Controversies and Questions Surrounding the use of Direct Oral Anticoagulants.* Presented as a grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, April 2017.
16. *Reviewing a Manuscript.* Presented to The Nebraska Medical Center pharmacy residents, Omaha, NE, September 2015.
17. *Use of Target Specific Anticoagulants in Reducing Stroke with Atrial Fibrillation.* Presented as a grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, February 2015.
18. *Antithrombotic Therapy in Patients Undergoing PCI.* Presented as a grand rounds to the UNMC/Nebraska Medicine Cardiology Department, Omaha, NE, January 2015.
19. *Interactive Teaching Techniques: No Bells or Whistles Needed.* Presented as part of a UNMC faculty development workshop on teaching, Omaha, NE, September 2014.
20. *Reviewing a Manuscript.* Presented to The Nebraska Medical Center pharmacy residents, Omaha, NE, September 2014.
21. *How to Prepare for a Journal Club Presentation.* Presented to The Nebraska Medical Center pharmacy residents, Omaha, NE, August 2014.
22. *Reviewing a Manuscript.* Presented to The Nebraska Medical Center pharmacy residents, Omaha, NE, August 2013.
23. *New Oral Anticoagulants in the Prevention and Treatment of Thrombosis.* Presented at the Preceptor and Alumni of the University of Nebraska Medical Center College of Pharmacy Continuing Education Program, Omaha, NE, October 2013.
24. *Reviewing a Manuscript.* Presented to The Nebraska Medical Center pharmacy residents, Omaha, NE, September 2012.
25. *Rivaroxaban for the Treatment of Pulmonary Embolism.* Presented to The Nebraska Medical Center Cardiology/Critical Care Pharmacy Team, Omaha, NE, March 2012.
26. *Writing an Article.* Presented to Omaha area pharmacy residents as part of the UNMC Teaching Certificate Program, Omaha, NE, January 2012.
27. *Reviewing a Manuscript.* Presented to The Nebraska Medical Center pharmacy residents, Omaha, NE, August 2011.
28. *VTE Prevention – Clinical Evidence and Clinical Issues.* Presented as noon conference grand rounds to the medical staff at St. Elizabeth's Hospital, Lincoln, NE, April 2011.
29. *VTE Prophylaxis & Care of the Patient with VTE.* Presented as part of the nurses education day at The Nebraska Medical Center, Omaha, NE, January 2011.

30. *Reviewing a Manuscript.* Presented to The Nebraska Medical Center residents, Omaha, NE, June 2010.
31. *Teaching Cardiogenic Shock and Arrhythmia Using a Patient Simulation (SIMMAN) and Audience Response Systems.* Presented to the District 5 Colleges of Pharmacy representatives, Omaha, NE, August 2009.
32. *Writing an Article.* Presented to Omaha area pharmacy residents as part of the UNMC Teaching Certificate Program, Omaha, NE, June 2009.
33. *VTE Prevention in Medically Ill Patients with Chronic Respiratory Disease.* Presented as noon conference to the department of family practice physicians and residents at University of Nebraska Medical Center, Omaha, NE, May 2009.
34. *Teaching Cardiogenic Shock and Arrhythmia Using a Patient Simulation (SIMMAN) and Audience Response Systems.* Presented to the UNMC Chancellor's Board for Education, Omaha, NE, April 2009.
35. *Writing a Review Article.* Presented to faculty and staff of the University of Nebraska Medical Center Pharmacy Practice and Pharmaceutical and Nutrition Care Departments, Omaha, NE, December 2008.
36. *Understanding and Managing Heart Failure as a Comorbidity in Practice – Management of Chronic Heart Failure.* Presented to physicians, pharmacists, nurses, and physical therapist live at the University of Nebraska Medical Center, Omaha, NE and via telehealth network to Grand Island, Kearney, Norfolk, Chadron, Cozad, and Ogallala, NE, October 2008.
37. *VTE Prevention in High-Risk Patients.* Presented to nurses at the University of Nebraska Medical Center, Omaha, NE, July 2008.
38. *Oral Antiplatelet Therapy in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome.* Presented as noon conference to the department of family practice physicians and residents at University of Nebraska Medical Center, Omaha, NE, April 2008.
39. *VTE Prevention in High-Risk Patients.* Presented to the DVT Prophylaxis Six Sigma Group at the University of Nebraska Medical Center, Omaha, NE, April 2008.
40. *VTE Prophylaxis in Orthopedic Surgery.* Presented to physicians, nurses, and pharmacists at the Nebraska Medical Center Orthopedic Hospital, Omaha, NE, January 2008.
41. *Oral Antiplatelet Therapy in the Management of Acute Coronary Syndrome.* Presented to nurse practitioners at University of Nebraska Medical Center, Omaha, NE, April 2007.
42. *VTE Prophylaxis in High-Risk Medical Patients.* Presented to nurse practitioners at University of Nebraska Medical Center, Omaha, NE, March 2007.
43. *Bridging Therapy: What, When, and How?* Presented to the department of internal medicine at University of Nebraska Medical Center, Omaha, NE, March 2006.
44. *Low Molecular Weight Heparin Use in Acute Coronary Syndrome Patients.* Presented to the department of cardiology at University of Nebraska Medical Center, Omaha, NE, June 2005.
45. *VTE Prophylaxis in Medically Ill Patient – Why and How?* Presented to the pharmacy department of the Nebraska Medical Center, Omaha, NE, May 2005.

46. *Bridging Therapy: What, When, and How?* Presented to nurse practitioners at University of Nebraska Medical Center, Omaha, NE, March 2005.
47. *OASIS-5: Fondaparinux vs. Enoxaparin in UA/NSTEMI.* Presented to cardiologist at St. Luke's Hospital, Chesterfield, MO, October 2004.
48. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, October 2004.
49. *OASIS-5: Fondaparinux vs. Enoxaparin in UA/NSTEMI.* Presented to emergency room physicians at St. Luke's Hospital, Chesterfield, MO, September 2004.
50. *Glycoprotein IIb/IIIa Inhibitors: Why, When, and Which One?* Presented to the pharmacy department of St. Luke's Hospital, Chesterfield, MO, August 2004
51. *Management of Acute Myocardial Infarction. A Focus on the ACC/AHA Guidelines for Management of STEMI.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, August 2004.
52. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, June 2004.
53. *The Use of LMWH in Special Populations.* Presented to the pharmacy department of St. Luke's Hospital, Chesterfield, MO, April 2004.
54. *The Use of LMWH in Obese Patients.* Presented to medical staff of St. Luke's Hospital, Chesterfield, MO, March 2004.
55. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, February 2004.
56. *The Use of LMWH in Patients with Severe Renal Impairment.* Presented to medical staff of St. Luke's Hospital, Chesterfield, MO, February 2004.
57. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, October 2003.
58. *Low Molecular Weight Heparin for UA/NSTEMI: What to do in the Cardiac Cath Lab?* Presented to intensive care and telemetry floor nurses at St. Luke's Hospital, Chesterfield, MO, September 2003.
59. *Low Molecular Weight Heparin for UA/NSTEMI: What to do in the Cardiac Cath Lab?* Presented to cardiologists and cardiovascular surgeons at St. Luke's Hospital Cardiac Cath Conference, Chesterfield, MO, September 2003.
60. *Injectable Anticoagulants in Cardiology.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, August 2003.
61. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, June 2003.
62. *Stable Tachycardias.* Presented to advanced cardiac life saving instructor course at St. Luke's Hospital, Chesterfield, MO, April 2003.
63. *Update on the Management of Hypertension.* Presented to medical staff of St. Luke's Hospital, Chesterfield, MO, February 2003.

64. *Use of Nesiritide For Treatment of Heart Failure.* Presented to emergency department nurses at St. Luke's Hospital, Chesterfield, MO, January 2003.
65. *Update on the Use of LMWHs, Which Ones and When.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, January 2003.
66. *ACC/AHA Guidelines for the Treatment of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, October 2002.
67. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, October 2002.
68. *Role of BNP in Management of Heart Failure.* Presented to medical staff of St. Luke's Hospital, Chesterfield, MO, September 2002.
69. *Use of Nesiritide For Treatment of Heart Failure.* Presented to intensive care and telemetry floor nurses at St. Luke's Hospital, Chesterfield, MO, August 2002.
70. *Anticoagulation Review.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, July 2002.
71. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, June 2002.
72. *Inhaled Medications.* Presented to telemetry floor nurses at St. Luke's Hospital. Chesterfield, MO, February 2002.
73. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, February 2002.
74. *Advancing the Treatment of Severe Sepsis.* Presented to medical staff of St. Luke's Hospital, Chesterfield, MO, January 2002.
75. *Reperfusion Therapy for ST-Segment Elevation Acute Myocardial Infarction.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, December 2001.
76. *Advanced Cardiac Life Saving: Pharmacology.* Presented at St. Luke's Hospital ACLS re-certification course, Chesterfield, MO, October 2001.
77. *Advancing the Treatment of Severe Sepsis.* Presented to St. Luke's Hospital Pharmacy department, Chesterfield, MO, July 2001.
78. *Update on ACLS Guidelines and the Use of IV Amiodarone.* Presented to St. Luke's Hospital Cardiac Catheterization Laboratory nurses, Chesterfield, MO, July 2001.
79. *Advancing the Treatment of Severe Sepsis.* Presented to St. Luke's Hospital ICU sub-committee, Chesterfield, MO, July 2001.
80. *IV Amiodarone.* Presented to St. Luke's Hospital cardiology nurses, Chesterfield, MO, June 2001.
81. *National Cholesterol Education Program (NCEP) Update: Adult Treatment Program III.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, June 2001.
82. *ACLS Update.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, June 2001.

83. *Outcomes Associated with a Change in Selection of Glycoprotein IIb/IIIa Agents at St. Luke's Hospital.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, May 2001.
84. *ACLS Update.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, April 2001.
85. *LMWH: When and How they Should be Used.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, March 2001.
86. *ACLS Update: Treatment of Ventricular Fibrillation and Pulseless Ventricular Tachycardia.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, February 2001.
87. *Treatment of Myocardial Infarction in the New Millennium.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, January 2001.
88. *Use of LMWH in the Outpatient Setting.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, November 2000.
89. *Anticoagulation Review: How to Use Warfarin.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, August 2000.
90. *Anticoagulation Review: How to use Heparin and LMWH.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, August 2000.
91. *Angiotensin Converting Enzyme Inhibition and Cardiovascular Disease.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, May 2000.
92. *Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, April 2000.
93. *Spironolactone for the Treatment of Congestive Heart Failure.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, October 1999.
94. *Nutritional Supplements and Cardiovascular Disease.* Presented to St. Luke's Hospital Congestive Heart Failure Management Center Team, Chesterfield, MO, October 1999.
95. *Hypertension: A Review of JNC VI.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, October 1999.
96. *Hypertension: A Review of JNC VI.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, September 1999.
97. *Infectious Disease Concepts and Treatment.* Presented to St. Luke's Hospital pharmacists, Chesterfield, MO, July 1999.
98. *Prevention of Coronary Heart Disease Events with Hormone Replacement Therapy.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, June 1999.
99. *Diabetes Update.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, March 1999.
100. *Use of Amiodarone in Prehospital Cardiac Arrest.* Presented to St. Luke's Hospital emergency room nursing staff, Chesterfield, MO, January 1999.
101. *Levofloxacin vs. Ciprofloxacin at St. Luke's Hospital.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, January 1999.

102. *Initiation of Warfarin Therapy, 5-5 vs. 10-10.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, November 1998.
103. *Glycoprotein IIb/IIIa Blockers in Acute Coronary Syndromes.* Presented to Unity Health Care Cardiology Group, Chesterfield, MO, October 1998.
104. *An Evaluation of the Safety and Efficacy of Abciximab at St. Luke's Hospital.* Presented to St. Luke's Hospital Cardiac Cath Conference, Chesterfield, MO, August 1998.
105. *An Evaluation of the Use of Abciximab as an Adjunct to Percutaneous Transluminal Coronary Angioplasty at St. Luke's Hospital.* Presented to St. Luke's Hospital Cardiac Cath Conference, Chesterfield, MO, August 1998.
106. *Pain Management.* Presented to Surrey Place nursing staff, Chesterfield, MO, July 1998.
107. *Advancing the Battle Against Acute Coronary Syndromes: The GP IIb/IIIa Inhibitors.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, June 1998.
108. *Warfarin Reversal.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, May 1998.
109. *Warfarin Drug Interactions.* Presented to St. Luke's Hospital medical staff, Chesterfield, MO, February 1998.
110. *Weight Based Heparin Protocol.* Presented to St. Luke's Hospital nursing staff, Chesterfield, MO, December 1997.
111. *Guidelines for the Diagnosis and Management of Asthma: Review of the Expert Panel Report II.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, October 1997.
112. *Initiating Warfarin Therapy.* Presented to St. Luke's Hospital internal medicine residents, Chesterfield, MO, August 1997.

COMMITTEE APPOINTMENTS

University of Nebraska Medical Center

Conflict of Interest Committee 2019 – Present

University of Nebraska Medical Center College of Pharmacy

Academic Discipline Committee (Chair)	2019 – 2021
Faculty Parliamentarian	2019 – 2020
Curriculum Committee	2018 – Present
Pharmacotherapy Task Force (Chair)	2017 – 2021
Academic Performance Committee	2017 – 2020
Pharmacy Practice Faculty Search Committee (Chair)	2014 – 2017
Faculty Development Committee	2014 – 2019
Professionalism Task Force	2013 – 2014
Scholarship, Honors, and Financial Aid Committee (Chair)	2012 – 2014
Scholarship, Honors, and Financial Aid Committee	2009 – 2015
Student Discipline Committee	2009 – 2012
Grade Appeals Committee	2009 – 2017
Pharmacy Practice Chair Advisory Committee	2007 – 2016
Educational Task Force (Chair)	2008
Pharmacy Practice Chair Search Committee (Chair)	2006 – 2007
Admissions Committee	2005 – 2009

Search Committees 2005 – 2006, 2008, 2022

Nebraska Medicine

Cardiology/Neurology Team 2020 – Present
Residency Preceptor Committee 2016 – Present
Heart Failure Readmission Task Force 2010 – 2015
DVT Prophylaxis Six Sigma Project 2007 – 2009
Anticoagulation Management 2007 – 2018
Residency Advisory Committee (RAC) 2005 – 2007

Saint Louis College of Pharmacy

Progression Committee (Chair) 2000 – 2004
Awards Committee 2000 – 2002
Admissions Committee 1998 – 2000
Scholarship Committee (Chair) 2004
Residency Task Force (Chair) 2003 – 2004
Division Director Search Committee 2003 – 2004
Didactic Task Force 2002 – 2003
Residency Committee 2001 – 2004
Advisory Committee 1999 – 2001, 2002 – 2004
Promotion and Tenure Committee 1998 – 2002, 2004
Medicine Clerkship Task Force (Chair) 1998 – 2000
Communications Committee 1997 – 2004

Saint Luke's Hospital

Cardiovascular Research 2002 – 2004
ICU Committee 2002 – 2004
Congestive Heart Failure Team 2000 – 2004
Cardiovascular Clinical Guidelines Committee 1999 – 2004
PE / DVT Task Force 1997 – 1999
Pharmacy and Therapeutics Committee 1997 – 2004

American College of Clinical Pharmacy

UNMC Student Organization Faculty Advisor 2020 – Present
Mentoring Program – Mentor 2012 – 2013
Clinical Pharmacy Challenge Reviewer's Panel 2011 – 2015
FCCP Credentials Committee 2010 – Present
Task Force on Creating Residencies 2008 – 2010
2007 Spring Forum Program Abstract Chair 2005 – 2007
Abstract Reviewer 2005 – Present
Task Force on Critical Pathways (Chair) 2004 – 2006
Task Force on Residencies 2002 – 2004
Constitution and Bylaws Committee 2001 – 2002
Regional Recruiter 2000 – 2004
Task Force on Measuring Clinical Pharmacy Productivity 2000 – 2001
Full member 1998 – Present
Critical Care PRN – member 2015 – Present
Adult Medicine PRN – member 2000 – Present
Cardiology PRN – member 1999 – Present

ACCP Cardiology Practice Research Network (PRN)

Research and Scholarship Committee 2015 – Present
Journal of Pharmacy Practice liaison 2016 – Present
Publications Subcommittee (Chair) 2013 – 2015
Collaboration Task Force 2013 – 2015
Nominations Committee (Chair 2014) 2012 – 2014

Walk Rounds Committee	2012 – Present
Focus Session Committee	2011 – 2013
Cardiology PRN Chair	2012 – 2013
Cardiology PRN Chair-Elect	2011 – 2012
Spring 2006 Focus Session Program Committee – Chair	2005 – 2006

American Heart Association

Pharmacology Committee Chair-elect	2021 – Present
Pharmacology Committee	2018 – Present
Fellow (FAHA)	2021 – Present
Professional Education Committee	2021 – Present
Fellowship Review Committee	2020 – Present
Grant Reviewer	2015
Member	1999 – Present

American College of Cardiology

Fellow (FACC)	2021 – Present
CVT Educational Committee	2006 – Present
Anticoagulation Committee	2015 – 2020
Abstract Reviewer	2020 – Present
Nebraska ACC Member	2021 – Present
Member	2004 – Present

Midwest College of Clinical Pharmacy

Acting President	2006
President-elect	2005

Gateway College of Clinical Pharmacy

Acting President	2000
Nominations Committee (chair)	2000
President-elect	1999
Constitution and Bylaws Committee	1999 – 2000
Pharmacotherapy Exam Study Group (chair)	1998

OTHER PROFESSIONAL ACTIVITIES

Chapter Reviewer for: Coons JC, Verlinden NJ. Medication management during PCI. Cardiology Self-Assessment Program (CardsSAP), American College of Clinical Pharmacy, 2021

Pharmacotherapy Board Preparatory Course Mock Exam Work Group, 2021

Faculty Panel Chair for the Critical Care Self-Assessment Program (CCSAP) Book 1 in Cardiovascular Critical Care, 2019 – 2021.

Field tester for the Cardiology Board Certification Course, 2019 – 2021.

Faculty for the Pharmacotherapy Board Preparatory Course – Anticoagulation, 2018 – 2021

Faculty for the Cardiology Board Preparatory Course – Anticoagulation, 2018 – 2021

Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT) Planning Committee 2017 and 2018.

Chapter Reviewer for: Beavers CJ. Transitions of care after acute coronary syndrome and heart failure hospitalizations. Ambulatory Care Self-Assessment Program (ACSAP), American College of Clinical Pharmacy, 2017

Chapter Reviewer for: Dunn S, Kazmi H. Optimal use of antithrombotic therapies in acute coronary syndrome. Critical Care Self-Assessment Program (CCSAP), American College of Clinical Pharmacy, 2017.

Pharmacy representative for the Nebraska Mission – Lifeline Task Force and Hospital Advisory Committee through the Nebraska American Heart Association 2016 – 2020

Grant reviewer for the NIH Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section, 2015

Board of Pharmaceutical Specialties. Workgroup for defining standards for eventual board certification in Cardiology, 2012 – 2013.

American College of Clinical Pharmacy Clinical Pharmacy Career Path Roundtables – Cardiology, 2012 (Hollywood, FL), 2013 (Albuquerque, NM)

Served as evaluator for the American College of Clinical Pharmacy Student Awards, 2010 – 2012.

2009 Performance Improvement Workshops: Improving Patient Outcomes in Thromboembolic Disorders. Presented in Bethesda, MD, May 2009, Boston, MA, October 2009, and Morristown, NJ, October 2009.

American Board of Medical Specialties. Episodes and Cost of Care – Chronic Stable Angina Workgroup for the development of cost of care quality measures, 2009.

Pharmacist workshop – Optimizing Anticoagulation in Acute Coronary Syndrome. Presented in Bethesda, MD, April 2008, Washington D.C., August 2008, Atlanta, GA, September 2008, and Minneapolis, MN, October 2008.

Research platform presentation moderator at the American College of Clinical Pharmacy Annual Meeting, Denver, CO, October 2007.

Medical Mission Expedition, Belize, June 2005 – 2009, 2012, 2013, 2016, and 2019.

Pharmacotherapy Review of Stable Angina Pectoris and Acute Coronary Syndromes. Presented to the Gateway College of Clinical Pharmacy BCPS study group, St. Louis, MO, July 1998, June 1999, May 2000, June 2001, June 2003, and August 2004. Presented to the University of Nebraska Medical Center study group, Omaha, NE, March 2007.

Pharmacotherapy Review of Congestive Heart Failure. Presented to the Gateway College of Clinical Pharmacy BCPS study group, St. Louis, MO, June 2001, and September 2004. Presented to University of Nebraska Medical Center study group, Omaha, NE, March 2007.

Pharmacotherapy Review of Treatment of Arrhythmias. Presented to the Gateway College of Clinical Pharmacy BCPS study group, St. Louis, MO, June 2001, July 2003, and September 2004. Presented to University of Nebraska Medical Center study group, Omaha, NE, August 2007.

Local ASHP Clinical Skills Competition Judge, 1997 - 1999, 2001 – 2002, 2010, 2019

Item Writing Committee for National Association of Boards of Pharmacy, July 1999

Editorial Board Member for <i>Pharmacotherapy</i>	2007 – Present
Editorial Board Member for <i>Journal of Pharmacy Practice</i>	2014 – Present

Journal reviewer, <i>Clinical Therapeutics</i>	2020 – Present
Journal reviewer, <i>Thrombosis Research</i>	2019 – Present
Journal reviewer, <i>Clinical and Applied Thrombosis/Hemostasis</i>	2019 – Present
Journal reviewer, <i>Journal of Thrombosis and Thrombolysis</i>	2017 – Present
Journal reviewer, <i>Journal of Thrombosis and Haemostasis</i>	2016 – Present
Journal reviewer, <i>Clinical Pharmacokinetics</i>	2016 – Present
Journal reviewer, <i>Drugs</i>	2011 – Present
Journal reviewer, <i>Expert Opinion in Pharmacotherapy</i>	2011 – Present
Journal reviewer, <i>International Journal of Cardiology</i>	2010 – Present
Journal reviewer, <i>American Journal of Managed Care</i>	2010 – Present
Journal reviewer, <i>American Journal of Health-Systems Pharmacy</i>	2007 – Present
Journal reviewer, <i>Journal of Managed Care Pharmacy</i>	2005 – Present
Journal reviewer, <i>Pharmacy and Therapeutics</i>	2001
Journal reviewer, <i>Pharmacotherapy</i>	1999 – Present
Journal reviewer, <i>Annals of Pharmacotherapy</i>	1996 – Present

PROFESSIONAL MEMBERSHIPS

Society of Critical Care Medicine	2007 to 2020
American Heart Association	1999 to Present
Midwest College of Clinical Pharmacy	2005 to Present
Gateway College of Clinical Pharmacy	1997 to 2004
American Association of Colleges of Pharmacy	1997 to 2003
American College of Clinical Pharmacy (full member)	1996 to Present
American Society of Health Systems Pharmacist	1993 to Present
South Dakota Society of Health Systems Pharmacists	1994 to 1998

LICENSURE and CERTIFICATION

Registered Pharmacist, Nebraska	No. 12383
Registered Pharmacist, South Dakota	No. 4843
Board Certified Cardiology Pharmacist	2019 to Present
Board Certified Pharmacotherapy Specialist (BCPS)	1998 to Present
Added Qualifications in Cardiology	2006 to 2018
Advanced Cardiac Life Support (ACLS) Instructor	1997 to 2006
Advanced Cardiac Life Support (ACLS)	1995 to 2006
Basic Cardiac Life Support (BLS)	1994 to Present

HONORS AND AWARDS

Outstanding Teaching Award – University of Nebraska Medical Center	2021
Fellow of the American College of Cardiology	2021
Fellow of the American Heart Association	2021
Distinguished Teaching Award – University of Nebraska College of Pharmacy	2020
South Dakota State University College of Pharmacy and Allied Health	
Professions Distinguished Alumnus Award	2020
Distinguished Teaching Award – University of Nebraska College of Pharmacy	2017
ACCP Cardiology PRN Mentor Award	2016
Distinguished Teaching Award – University of Nebraska College of Pharmacy	2015
ACCP Cardiology PRN Outstanding Paper of the Year Award	2014
Outstanding Teaching Award – University of Nebraska Medical Center	2013
Distinguished Teaching Award – University of Nebraska College of Pharmacy	2012
Keynote Speaker of UNMC College of Pharmacy White Coat Ceremony – <i>What Now?</i>	2011
Distinguished Teaching Award – University of Nebraska College of Pharmacy	2010
Nominated for the Alvin M. Earle Outstanding Health Sciences Educator Award	2008
Distinguished Teaching Award – University of Nebraska College of Pharmacy	2007

Fellow of the American College of Clinical Pharmacy	2004
Clinical Pharmacy Preceptor of the Year Award – St. Louis College of Pharmacy	2000
Outstanding Pharm.D. Student Award – South Dakota State University	1996